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The miR-34 family is directly transactivated by tumor suppressor p53, which is frequently 
mutated in the majority of human cancers, including epithelial ovarian cancer (EOC). MET 
receptor protein tyrosine kinase is one of the common targets of miR-34 family. MET activation 
is frequently implicated in increased motility and invasion of cancer cells and is associated with 
poor prognosis of EOC patients. However, it remains uncertain if dysregulation of p53/miR-
34/MET signaling pathway plays an important role in EOC pathogenesis.  
During our studies, we have found frequent downregulation of miR-34 in human EOC. 
Reduced expression of miR-34 family was associated with p53 mutations, promoter methylation 
and copy number variations. At the same time, levels of miR-34a and MET expression were 
inversely correlated in EOC specimens. miR-34 reconstitution in p53 deficient ovarian cancer 
cells resulted in reduced proliferation, motility and invasion, the latter of which was dependent 
on MET expression. 
Consistently, we were able to find an increase of MET expression in the mouse ovarian 
surface epithelium after conditional p53 inactivation, resulting in increased cell motility and 
invasion. Concomitant inactivation of Met and p53 abrogated this feature, suggesting that MET 
activation was responsible for p53 control of cell motility and invasion. In addition to miR-34-
dependent regulation of MET, we also identified miR-34-independent mechanism, in which p53 
inhibits SP1 binding to MET promoter. miR-34-dependent and -independent mechanisms are 
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not functional in p53 absence, while mutant p53 proteins retain partial MET promoter 
suppression. Accordingly, MET expression, cell motility and invasion were particularly high in 
p53 null cells, as compared to cells expressing mutant p53 protein. This finding may provide a 
mechanistic explanation to reports of poorer prognosis of patients with p53 null EOC as 
compared to those expressing mutant p53. 
In order to further explore the role of miR-34 family in development and carcinogenesis, 
mice carrying conventional and conditional targeted mutations of mir-34 genes were generated. 
mir-34a-/- mir-34b/c-/- mice are viable and exhibit phenotypes not typical for those associated 
with p53 null background. Specifically, mice do not develop early onset lymphomas but manifest 
hypoplasia of the white pulp in the spleen, accelerated thymic aplasia, focal hyperplasia of 
Purkinje neurons and ulceration of the forestomach, indicating miR-34 importance for a number 
of biological processes. Loss of mir-34 resulted in increased cell proliferation, similar to that 
after p53 loss. However, unlike p53 deficiency, lack of mir-34 did not increase induced 
pluripotent stem (iPS) cell reprogramming efficiency, suggesting that p53 may affect 
reprogramming by other mechanisms, in addition to increased proliferation. Our observations 
that mir-34b/c deficiency caused radioresistant phenotype after 15 Gy ionizing radiation also 
indicate that miR-34 role in DNA damage response is distinct from that of p53,  
Taken together, we have shown that p53/miR-34/MET signaling pathway plays an 
important role in human EOC. Furthermore, we have identified miR-34-dependent and miR-34-
independent mechanisms of MET regulation by p53 and determined that existence of such 
mechanisms may explain uneven patient prognosis as a function of p53 mutation type. Finally, 
generation of mir-34 deficient mice allowed us to determine new biological functions of miR-34 
during development and DNA damage response, laying ground for future studies aimed to 
reveal miR-34 roles in development, DNA damage response and carcinogenesis. 
v 
 
BIOGRAPHICAL SKETCH 
 
Chang-Il Hwang was born on October 9th, 1977, in Seoul, South Korea. Dedicated to a career 
in Biomedical Sciences, Chang-Il obtained his Doctoral degree in Veterinary Medicine from 
Seoul National University. Having more interests in biomedical research, he pursued master 
degree in Biochemistry and Molecular Biology in College of Medicine, Seoul National University. 
As a part of military service required for all Korean men, he worked at Biomedlab Co., a bio-
company manufacturing diagnostic microarrays for two and half years. In 2006, Chang-Il came 
to USA and started to pursue his Ph.D. degree at Cornell University, Ithaca, NY, where he 
joined the laboratory of Dr. Alexander Nikitin to study the role of p53 and miR-34 in mouse 
models of human cancer.  
vi 
 
ACKNOWLEDGEMENTS 
 
I would like to thank my advisor, Dr. Alex Nikitin for his guidance and encouragements on my 
research project. This thesis would not have been possible without his help, support and 
patience. I also thank my committee members, Drs. John Lis, Paul Soloway and Roy Levine for 
their guidance and suggestions.  
Also I would like to thank all former and current Nikitin lab members, Andrea, Andres, Dave, 
Zongxiang, Jinhyang, Le, Chieh-Yang, Sam, Ben, Eric, Meredith, Diana and Hua for their 
supports and help, whenever needed.  
I acknowledge the college of veterinary medicine, Cornell university for Graduate Research 
Assistantship as a financial support during three and half years. 
It is a pleasure to thank those who made this thesis possible. I acknowledge Dr. John Schimenti 
and his research associate Rob Munroe for assistance with generating chimeric mice; Dr. 
Weipeng Mu, a former graduate student in Schimenti lab for helping me to construct mir-34a 
targeting vector; Christian Abratte, Cornell iPS core facility for all iPS cell related experiments; 
Drs. Anil Sood, Lora Ellenson, Andrew Godwin for the kind gift of ovarian cancer specimen; Dr. 
Heiko Hermeking for providing mir-34a conditional knock-out mice, miR-34 promoter 
methylation studies and critical comments on my research; Dr. Wei Wang, Cornell microarray 
core facility for assistance with microarray data analysis; Dr. Samuel Mok for his kind gift of 
human ovarian cancer cell lines; Drs. Paolo Comoglio and Carla Boccaccio for providing human 
MET promoter constructs and valuable comments on my work; Dr. Bert Vogelstein for his kind 
gifts of p53 expression vectors and reporter constructs; Dr.  Snorri Thorgeirsson for Met 
conditional knock-out mice.  
vii 
 
I thank my parents, parents-in-law and grandmother for their supports, prayers and 
encouragements. I would like to deeply thank to my family especially my wife, Eunjung Lee and 
my twin sons, Timothy and Theodore for their encouragements and love. 
Lastly, I offer my regards and blessings to all of those who supported me in any respect during 
the completion of the project. 
  
viii 
 
TABLE OF CONTENTS 
Biographical sketch v 
Acknowledgements vi 
Table of Contents viii 
List of Figures x 
List of Tables xiii 
List of Abbreviations xiv 
   
Chapter 1   
 Introduction  
 1.1 p53 and ovarian cancer 1 
 1.2 miR-34 family and cancer and therapeutic promises 4 
 1.3 Transcriptional repression of p53 7 
 1.4 p53, a master regulator of cell motility and invasion 12 
 1.5 iPS cells reprogramming, p53 and miR-34 13 
 1.6 Concluding remarks and project overview 15 
 1.7 References 17 
   
Chapter 2   
 Frequent downregulation of miR-34 family in human ovarian cancers  
 2.1 Abstract 35 
 2.2 Introduction 36 
 2.3 Materials and methods 37 
 2.4 Results 42 
 2.5 Discussion 61 
 2.6 References 66 
   
Chapter 3   
 Wild-type p53 controls cell motility and invasion by dual regulation of 
MET expression 
 
 3.1 Abstract 73 
 3.2 Introduction 74 
 3.3 Materials and methods 75 
 3.4 Results 82 
 3.5 Discussion 117 
 3.6 References 119 
   
Chapter 4   
 Generation and characterization of mice with conventional and 
conditional inactivation of mir-34 family 
 
 4.1 Abstract 128 
 4.2 Introduction 129 
 4.3 Materials and methods 132 
 4.4 Results 137 
 4.5 Discussion 162 
 4.6 References 169 
   
Chapter 5   
 Summary and future directions  
ix 
 
 5.1 Summary 178 
 5.2 Future directions 180 
 5.3 References 189 
  
x 
 
LIST OF FIGURES 
 
Figure 2.1 miR-34 is downregulated in EOC and associated with metastatic clinical stage 45 
Figure 2.2 miR-34b and miR-34b* are present in equal amounts and are highly correlated 47 
Figure 2.3 miR-199a* is not significantly altered in EOC 48 
Figure 2.4 miR-34 family expression in different EOC subtypes 50 
Figure 2.5 miR-34 promoter methylation and copy number variations are common in EOC 53 
Figure 2.6 miR-34a expression is inversely associated with MET expression in EOC 55 
Figure 2.7 miR-34 reconstitution decreases migration, invasion and proliferation in EOC 
cells 
58 
Figure 2.8 miR-34 family reduces invasion 60 
Figure 2.9 Apoptosis is unaffected by miR-34 reconstitution 62 
Figure 3.1 Inactivation of p53 leads to increase of MET expression 83 
Figure 3.2 Gene expression profile of p53 inactivated OSE cells 85 
Figure 3.3 Effect of p53 knockdown on MET expression in human cancer cells 
expressing wild-type p53 and OSE morphology 
89 
Figure 3.4 MET is essential for p53 inactivation-mediated cell motility and invasion 90 
Figure 3.5 p53 inactivation increases cell motility along with increased MET expression 
and MET phosphorylation 
92 
Figure 3.6 Migration and invasion but not proliferation depends on MET presence after 
p53 inactivation 
93 
Figure 3.7 p53 has a miR-34-independent mechanism of MET regulation 96 
Figure 3.8 Ectopic p53 expression is comparable to endogenous p53 expression level 97 
Figure 3.9 miR-34 and p53 effects on MET expression and promoter activity 98 
Figure 3.10 p53 suppresses MET promoter activity 101 
xi 
 
Figure 3.11 MET promoter activity in OSN2 cells and involvement of SP1 in MET 
promoter activity 
103 
Figure 3.12 Hypoxia does not affect HIF1A and MET expression, and CD44 is not 
affected by p53 expression in OSE cells 
106 
Figure 3.13 p53 inhibits SP1 binding to MET promoter 109 
Figure 3.14 Contribution of mutant p53 protein to OSE motility and invasion depends on 
MET 
112 
Figure 3.15 The effect of mutant p53 on MET expression 114 
Figure 3.16 The role of mutant p53 in OSE cells 115 
Figure 4.1 mir-34a targeting strategy 139 
Figure 4.2 Validation of mir-34a conditional targeting construct in E.coli 142 
Figure 4.3 mir-34a targeting strategy and confirmation of correct homologous 
recombination 
143 
Figure 4.4 Genotyping of mice carrying conditional mir-34a allele and mir-34a null allele 145 
Figure 4.5 Body weights of wild-type (WT) and mir-34a-/-mir-34b/c-/- (TKO) female mice 149 
Figure 4.6 miR-34 expression in the brain (A) and the ovarian surface epithelium (OSE, 
B) of wild-type (WT) and mir-34a-/- mir-34b/c-/- (TKO) mice 
151 
Figure 4.7 Morphological changes in the spleen of mir-34a-/-mir-34b/c-/- mice (TKO) 152 
Figure 4.8 Morphological changes in the thymus of mir-34a-/- mir-34b/c-/- mice (TKO) 153 
Figure 4.9 Morphological changes in the stomach and the cerebellum of mir-34a-/-mir-
34b/c-/- mice (TKO) 
154 
Figure 4.10 iPS cell reprogramming efficiency of TTFs from wild-type and TKO  156 
Figure 4.11  iPS cell reprogramming efficiency of mouse embryonic fibroblasts (MEFs) 
from mir-34aloxP/loxPmir-34b/cloxP/loxP after Ad-Bl or Ad-Cre infection  
159 
Figure 4.12 H&E staining of small and large intestine after 15 Gy IR  160 
xii 
 
Figure 4.13 miR-34a in situ hybridization of small and large intestine after 15 Gy IR 161 
Figure 4.14 Survival analysis of 10 Gy (A) and 15 Gy (B) whole body exposure of IR in 
wild-type and mir-34b/c-/- 
163 
Figure 5.1 The pINDUCER lentiviral vector for inducible miR-34 system 183 
Figure 5.2 Proposed model for differential effect on feedforward loop regulation of MET 
by p53 status 
186 
 
 
  
xiii 
 
LIST OF TABLES 
 
Table 1.1 Clinical significance of miR-34 family downregulation is in human cancers 6 
Table 1.2 DNA binding-dependent and DNA binding-independent modes of 
transcriptional repression by p53 and their examples 
9 
Table 2.1 Characteristics of 83 patients with EOC 43 
Table 2.2 Sequences for primers used in this study 44 
Table 2.3 p53 mutation status of human samples 51 
Table 4.1 Genotypes of mice resulting from crosses between mir-34a-/-mir-34b/c+/- and 
mir-34a-/-mir-34b/c+/- mice 
146 
Table 4.2 Genotypes of mice resulting from crosses between mir-34a+/- mir-34b/c-/-and 
mir-34a-/- mir-34b/c+/- mice 
147 
Table 4.3 Genotypes of mice resulting from crosses between mir-34-/- mir-34b/c-/- with 
mir-34a-/- mir-34b/c+/- mice 
148 
  
xiv 
 
LIST OF ABBREVIATIONS 
 
AML Acute myeloid leukemia 
AP Alkaline phosphatase 
BAC Bacterial artificial chromosome 
ChIP Chromatin immunoprecipitation 
CLL Chronic lymphocytic leukemia 
DIG Digoxigenin 
EDC 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide 
EOC Epithelial ovarian cancer 
GI tract Gastrointestinal tract 
HGF Hepatocyte growth factor 
iPS Induced pluripotent stem 
IR Ionizing radiation 
LIF Leukemia inhibitory factor 
LNA Locked nucleic acid 
MEF Mouse embryonic fibroblast 
miRNA microRNA 
mitA Mithramycin A 
MSP Methylation specific PCR 
NSCLC Non-small-cell lung carcinoma 
OSE Ovarian surface epithelium 
p53 RE p53 response element 
qRT-PCR Quantitative reverse transcription polymerase chain reaction 
xv 
 
RISC RNA induced silencing complex 
rtTA tetracycline reverse transcriptional activator 
TKO Triple knock-out 
TTF Tail-tip fibroblast 
 
 
 
 
 
 
 
 
 
 
 
1 
 
CHAPTER 1 
 
INTRODUCTION 
 
1.1 p53 and ovarian cancer 
 
The p53 gene was first identified in 1979 as a target of the SV40 oncogenic virus (Linzer and 
Levine, 1979) and initially proposed as an oncogene (Eliyahu et al., 1984; Jenkins et al., 1984; 
Parada et al., 1984). Later, p53 has been shown to be an important tumor suppressor gene that 
functions as a key transcriptional regulator (Levine and Oren, 2009). As a transcription factor, 
p53 is able to bind to a consensus response element (p53 RE, two tandem copies of the 
sequence PuPuPuC(A/T)(A/T)GpyPyPy separated by a 0-13 bp) and transactivate target genes, 
such as p21, Mdm2, Puma, Bax and Gadd45. In addition, p53 is capable of repressing a large 
number of genes by either DNA binding or protein-protein interaction (described in Chapter 1.3), 
although molecular mechanisms of such repression remain poorly understood (Ho and 
Benchimol, 2003; Rinn and Huarte, 2011). Due to large number of its target genes, p53 plays a 
pivotal role in coordinating the cellular responses to a broad range of cellular process including 
cell cycle arrest, DNA repair, apoptosis, senescence and angiogenesis (Menendez et al., 2009).  
 p53 mutations are the most common genetic alteration in human cancers (Levine and 
Oren, 2009). p53 mutations frequently occur in DNA binding domain, resulting in loss of its 
function as a transcriptional activator. In addition to loss of function by rendering p53 inactive, 
some mutations result in proteins with new transcriptional properties, so called gain of function 
mutants (Reviewed in (Oren and Rotter, 2010; Vousden and Prives, 2009)). In some cancer 
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types, gain of function mutations have been reported to be associated with more aggressive and 
metastatic characteristics as compared to those in cancers with p53 null phenotype (Brosh and 
Rotter, 2009). However, it is controversial whether certain gain-of-function mutants predict 
poorer prognosis than p53 null in all human cancers  (Soussi and Beroud, 2001). Indeed, as 
compared to malignancies expressing mutant p53 protein, p53 null neoplasms have been 
shown to be associated with poorest prognosis in lung, breast and ovarian cancers (Hashimoto 
et al., 1999; Lai et al., 2004; Olivier et al., 2006; Rose et al., 2003; Rossner et al., 2009; Shahin 
et al., 2000; Sood et al., 1999).  
Ovarian cancer is the sixth most frequent female cancer worldwide, with 200,000 new 
cases diagnosed every year, and the most lethal of all gynecological cancers (Jemal et al., 2011; 
Jemal et al., 2010). Epithelial ovarian cancer (EOC) is the most common type of ovarian cancer, 
and is further classified into 4 different major groups (serous, mucinous, endometrioid and clear 
cell carcinoma) based on tumor cell morphology (Cho and Shih, 2009). Among these, high 
grade serous EOC is the most common type, and is characterized by high frequency of p53 
mutation, fast progression, and the poorest prognosis (Cho and Shih, 2009; Choi et al., 2008; 
Corney et al., 2008). The majority of EOC is believed to originate from the ovarian surface 
epithelium (OSE), a single layer of cuboidal cells coating the ovary (Auersperg et al., 2001; 
Nikitin et al., 2004).  
During ageing OSE frequently form inclusion cysts which are considered to be precursor 
lesions. Consistent with this possibility, overexpression of p53 is often found in such cysts 
(Okamura and Katabuchi, 2001). Supporting that p53 mutations are an early event during 
epithelial ovarian carcinogenesis they have been  also detected in early stage high grade 
serous adenocarcinomas, as well as in adjacent dysplastic epithelium of prophylactically 
removed ovaries from patients with BRCA1 heterozygosity (Werness et al., 2000). In agreement 
with critical roles of p53 in EOC pathogenesis, OSE-specific inactivation of p53, particularly 
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combined with Rb gene, results in malignant neoplasms closely resembling human high grade 
serous adenocarcinoma of the ovary according to their pathology, biological behavior and gene 
expression signatures (Flesken-Nikitin et al., 2003).  
Notably p53 mutation is mainly detected in high grade serous adenocarcinoma of the 
ovary, but is rarely present in low grade serous carcinoma. Since the latter neoplasm has 
frequent K-ras mutations but no p53 mutations, it is generally accepted that high and low grade 
carcinomas have distinct pathogenesis (Cho and Shih, 2009). At the same time, Pten mutations 
are present more frequently in endometrioid adenocarcinoma of the ovary. Consistent with 
association of specific genetic alterations particular tumor types, OSE-specific Pten inactivation 
combined with either mutated K-Ras expression or aberrant Wnt/beta-catenin signaling results 
in endometrioid carcinoma in genetically modified mice (Dinulescu et al., 2005; Wu et al., 2007).  
In addition to the OSE cell of origin, some EOC derive from the epithelium of the 
fallopian tube fimbria and other derivatives of the Mullerian tract based on recent morphologic, 
immunohistochemical and molecular genetic studies (Dubeau, 2008; Kurman and Shih Ie, 2011; 
Lee et al., 2007; Medeiros et al., 2006). A hypothesis unifying EOC origin from OSE and 
fallopian epithelium has been also proposed based on following observations  (1) the OSE and 
fimbrial epithelium have connection both developmentally and anatomically, (2) several 
differentiation markers are overlapped between two epithelia, particularly near their anatomic 
boundary, and (3) there are similar examples of transitional epithelia prone to neoplastic 
progression such as the squamo-columnar junction of the uterine cervix and the esophageal-
gastric junction (Auersperg, 2011; Auersperg et al., 2008). Unfortunately, no convincing 
experimental support of this hypothesis has been reported so far and the origin of EOC from cell 
types other than the OSE remains largely speculative. 
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The need for understanding pathogenesis of the ovarian cancer is particularly urgent  
because over 70% of ovarian cancer patients are diagnosed in advanced stage and shows poor 
survival rate (Jemal et al., 2010) mainly due to asymptomatic and rapid EOC progression. At the 
same time, patients diagnosed with EOC confined to the ovary (stage I) have significant 5 years 
survival ranging from 60% to 90%, similar to other common cancers. As discussed below, 
recent discovery of p53/miR-34 network as well as better understanding of p53 transrepression 
mechanisms has opened an exciting opportunity for development of better diagnostic, 
therapeutic and preventive approaches cancer in general and EOC in particular. 
 
1.2 miR-34 family in cancer and therapeutic promises 
 
miRNA is a family of small non-coding RNAs which comprise 22~24 nucleotide lengths. Primary 
transcripts of miRNAs are transcribed mostly by RNA polymerase II, and some by RNA 
polymerase III. This primary transcript is called pri-miRNA. Pri-miRNA is processed by Drosha, 
RNase III endonuclease in the nucleus, resulting in ~70 nt double stranded RNA molecules 
called pre-miRNA. Subsequently pre-miRNA is transported into cytoplasm by exportin-5, and 
further processed into ~22 nt RNA duplex by another RNase III endonuclease, Dicer. A mature 
form of miRNA is loaded into RNA induced silencing complex (RISC), and bind to 3’-UTR of 
target genes resulting in mRNA cleavage or translational inhibition (Bartel, 2004; Huntzinger 
and Izaurralde, 2011; Krol et al., 2010). Over 60% of mammalian mRNAs are predicted targets 
of miRNAs (Friedman et al., 2009). Depending on its target genes, effect of miRNA could be 
oncogenic or tumor suppressive. miRNAs were initially linked to tumorigenesis due to their 
proximity to chromosomal breakpoints (Calin et al., 2004b) and their dysregulated expression 
levels in many malignancies (Calin et al., 2004a; Lu et al., 2005). During recent years, the 
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involvement of miRNAs in cancer pathogenesis has become increasingly obvious (Corney and 
Nikitin, 2008; Garzon et al., 2010). 
One of the most intensively studied miRNAs is miR-34 family. miR-34 family is encoded 
by mir-34a gene located on human chromosome 1 and miR-34b and mir-34c genes located on 
human chromosome 11 (chromosomes 4 and 9, respectively, in mouse). miR-34a is transcribed 
alone, while miR-34b and miR-34b/c share a common primary transcript as a cluster. The first 
evidence for potential involvement of miR-34 family in cancer has arisen from reports of a 
minimal deleted region 11q23-q24-D containing mir-34b/c in lung and breast cancers (Calin et 
al., 2004b), and 1p37 containing mir-34a, frequently deleted in high-risk neuroblastoma (Cole et 
al., 2008; Welch et al., 2007). In 2007 several groups, including our laboratory, independently 
reported that miR-34 family is a direct target of p53 transactivation (Bommer et al., 2007; Chang 
et al., 2007; Corney et al., 2007; He et al., 2007; Tarasov et al., 2007).  
Consistent with miR-34 transactivation by p53, frequent downregulation of miR-34 
expression has been reported in ovarian cancer (Dahiya et al., 2008; Eitan et al., 2009; Iorio et 
al., 2007; Kuo et al., 2009; Zhang et al., 2008), non-small-cell lung carcinoma (Gallardo et al., 
2009; Landi et al., 2010; Mudduluru et al., 2011), leukemia (Chim et al., 2010; Mraz et al., 2009; 
Zenz et al., 2009), neuroblastoma (Cole et al., 2008; Welch et al., 2007), colorectal carcinoma 
(Toyota et al., 2008), oral carcinoma (Scapoli et al., 2011), head and neck carcinoma (Lujambio 
et al., 2008), gastric cancer (Suzuki et al., 2010) and pleural mesothelioma (Kubo et al., 2011). 
This downregulation was associated with p53 mutations, changes in expression of Myc, FoxP1 
and C/EBPα expression, mir-34 epigenetic inactivation or copy number variations (summarized 
in Table 1.1). Although p53 is a critical regulator to induce miR-34 family expression, a number 
of evidences support that there are more regulators of miR-34a and miR-34b/c such as c-Myc, 
C/EBPα, ELK1, p38 MAPK/MK2 and K-Ras (Cannell et al., 2010; Chang et al., 2008; 
Christoffersen et al., 2010; Kent et al., 2010; Pulikkan et al., 2010).  
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Table 1.1 Clinical significance of miR-34 family downregulation in human cancers  
Cancer Subtype 
 
miR-34 member  Mechanism Clinical significance  Reference 
Ovarian cancer 
 
 miR-34c ↓  ND* (Dahiya et al., 2008) 
Serous miR-34c ↓  ND (Iorio et al., 2007) 
 miR-34a ↓  Accelerated cancer  progression (Eitan et al., 2009) 
EOC miR-34a and b ↓  Accelerated cancer  progression (Zhang et al., 2008) 
Low grade EOC mir-34a hemizygous 
deletion 
Deletion ND (Kuo et al., 2009) 
EOC miR-34a ↓ p53 mutation, 
promoter methylation, 
and copy number 
variations 
ND Chapter 2 (Corney et 
al., 2010) 
EOC miR-34 b/c ↓ p53 mutation and  
promoter methylation  
 Accelerated cancer progression  Chapter 2 (Corney et 
al., 2010) 
Lung cancer 
 miR-34a and c ↓  Poor prognosis (Landi et al., 2010) 
NSCLC miR-34a ↓  Increased relapse rate (Gallardo et al., 2009) 
NSCLC miR-34a ↓ Promoter methylation ND (Mudduluru et al., 
2011) 
Stage I NSCLC miR-34b/c ↓ Promoter methylation Increased recurrence and poor 
survival 
(Wang et al., 2011) 
Leukemia 
CLL miR-34a ↓ p53 mutation ND (Mraz et al., 2009) 
CLL miR-34a ↓  Increased refractoriness to 
chemotherpay 
(Zenz et al., 2009) 
High grade B cell 
lymphoma 
miR-34a ↓ Myc and FoxP1 
overexpression 
ND (Craig et al., 2011) 
AML miR-34a ↓ C/EBPα mutation ND (Pulikkan et al., 2010) 
Neuroblastoma  mir-34a deletion Deletion ND (Cole et al., 2008)  mir-34a deletion Deletion ND (Welch et al., 2007) 
Colorectal cancer  miR-34b/c ↓ Promoter methylation ND (Toyota et al., 2008) 
Oral carcinoma  miR-34a ↓  ND (Scapoli et al., 2011) 
Pleural 
mesothelioma 
 miR-34a and b/c ↓ Promoter methylation ND (Kubo et al., 2011) 
Gastric cancer  miR-34b/c ↓ Promoter methylation ND (Suzuki et al., 2010) 
• NSCLC ; non-small-cell lung carcinoma, CLL; chronic lymphocytic leukemia, AML; acute myeloid leukemia 
• * ND, not determined 
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Target of miRNAs can be computationally predicted by base paring between seed sequence 
of miRNAs and target gene 3’-UTR sequence (Bartel, 2004). However, a perfect seed match by 
itself has been shown to be a poor predictor for miRNA regulation due to the large number of 
random occurrences of any given hexamer in 3’UTRs. Perfect seed complementarity is neither 
necessary nor sufficient for miRNA regulation. Due to imperfect computational algorithms and 
lack of knowledge of detailed mechanism, current target prediction algorithms predict too many 
false-positive target genes (up to 66%), even though miRNAs regulate relatively small number 
of proteins at modest levels (Chi et al., 2009). Therefore miRNA-target gene relationship should 
be experimentally validated. Since miR-34 has large number of target genes like any other 
miRNAs and its effects are known to regulate proliferation, cell cycle, senescence, cell motility 
and invasion, miR-34 family is an attractive drug target for therapeutic purpose. Since miR-34 
expression is reduced in many cancers, re-introduction of miR-34 into cancer tissue could 
provide a therapeutic benefit by restoring regulation of target genes. For example, miR-34a 
delivery has been shown to have tumor suppressive role in lung cancer models (Trang et al., 
2011; Wiggins et al., 2010), pancreatic cancer (Pramanik et al., 2011) and neuroblastoma cells 
(Tivnan et al., 2011). Replacement strategies require delivery vehicles for delivery of double-
stranded miRNA mimics. Due to intensive efforts to deliver siRNA prior to discovery of miRNAs, 
miRNAs seems ready to deliver systemically in vivo (Davis et al., 2010). In spite of similarity 
between miRNA and siRNA therapeutics, miRNA therapeutics have several advantages over 
siRNA approach, such as in vivo stability, highly RNA promoter-compatibility and no overt 
toxicity (Bader et al., 2010; Wang et al., 2009a).  
 
1.3 Transcriptional repression by p53 
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While the mechanism of how p53 transactivates the promoter of target genes is well understood, 
details of transrepression by p53 remain less clear. Unlike transactivation which involves DNA 
binding of p53 onto the well-defined p53 RE, transrepression can occur through either DNA 
binding or protein-protein interaction (Ho and Benchimol, 2003). Unfortunately, DNA binding 
consensus sequence of p53, which is required for p53 binding on promoter regions, does not 
determine if p53 binding is associated with transactivation or transrepression. Furthermore, 
there is a novel p53 binding site that is oriented in an alternating head-to-tail formation instead 
of the head-to-head arrangement of the canonical p53 RE for transcriptional suppression 
(Johnson et al., 2005). Examples of DNA binding-dependent and DNA binding-independent 
modes of transcriptional repression by p53 are summarized in Table 1.2. 
 
1.3.1 DNA binding-dependent, via canonical binding site mechanism 
 
Approximately 15% of the p53 REs are associated with transcriptional repression (Riley et al., 
2008). In this mode of repression, p53 DNA binding is required for transcriptional repression, 
and p53 REs are found in the promoter region. Although detailed mechanism still remains 
elusive, p53 may achieve transcriptional repression by two different DNA binding-dependent 
mechanisms. First, p53 is bound to p53 REs of promoter region, and subsequently recruits 
chromatin remodeling complexes. For example, in the Survivin promoter, upon DNA damage 
activated p53 is recruited in p53 RE of Survivin promoter, resulting in the recruitment of HDAC1, 
DNMT1 and histone methyltransferase G9a along with histone H3K9me2 (Esteve et al., 2007). 
In addition, Esteve et al. observed CpG island methylation in this region after p53 induction 
(Esteve et al., 2005). These results suggest that both DNA and histone methylation along with 
repressive complexes recruited by p53 mediates Survivin gene repression. Second, p53 compe-
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Table 1.2 DNA binding-dependent and DNA binding-independent modes of transcriptional repression by p53 and their examples 
Class Mechanism Gene Interacting or competing partner Reference 
DNA 
binding-
dependent 
Canonical 
Head-to-head 
orientation 
PuPuPuC(A/T) 
(A/T)GpyPyPy 
Chromating 
remodeling 
Survivin  (Esteve et al., 2007) 
PKD1  (van Bodegom et al., 2010; Van Bodegom et al., 2006) 
HSP90AB1/Hsp90b  (Zhang et al., 2004) 
Compete with 
other 
transcription 
factor 
miR-17-92 TBP (Yan et al., 2009) 
POLD1 Sp1 (Li and Lee, 2001) 
CDC25B NF-Y, Sp1 (Dalvai et al., 2011) 
Mn Superoxide 
dismutase Sp1 (Dhar et al., 2008) 
dUTPase Sp1 (Wilson et al., 2008) 
Noncanonical 
Head-to-tail orientation 
PuPuPu(A/T) 
PuPuPu(A/T) 
MDR1  (Johnson et al., 2005) 
CD44  (Godar et al., 2008) 
DNA 
binding-
independent 
Interaction with basal transcriptional 
machinery Rb  (Shiio et al., 1992) 
Inhibit other transcription factor binding
Beta-amyloid 
precursor protein Sp1 (Cuesta et al., 2009) 
MCL-1 Sp1 (Pietrzak and Puzianowska-Kuznicka, 2008) 
S100A6 Sp1, NF-kB (Kroliczak et al., 2008) 
hTERT Sp1 (Okawa et al., 2007) 
MGMT Sp1 (Bocangel et al., 2009) 
HIV-LTR Sp1 (Bargonetti et al., 1997) 
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tes with other transcription factor bindings. In this case, p53 RE is commonly located nearby 
other transcription factor binding sites, by which p53 binding prevents from other transcription 
factor bindings such as Sp1, NF-Y and TBP. For example, in the case of POLD1, MN 
Superoxide dismutase and dUTPase promoter, Sp1 binding site is located nearby p53 RE (Dhar 
et al., 2006; Li and Lee, 2001; Wilson et al., 2008). Gel shift assay and chromatin 
immunoprecipitation assay showed that p53 expression reduced Sp1 DNA binding onto the 
promoter region, suggesting that p53 occupancy in p53 RE competes with Sp1 DNA binding. 
Similar types of competition with TBP and NF-Y were also found in the promoter regions of miR-
17-92 cluster and Cdc25b respectively (Dalvai et al., 2011; Yan et al., 2009). 
 
1.3.2 DNA binding-dependent, via non-canonical binding site mechanism 
 
Recently, non-canonical p53 RE is first identified in the MDR1 gene (Johnson et al., 2005). 
While two copies of the sequence PuPuPuC(A/T) arranged head-to-head and separated by 0-
13 base pairs are original p53 REs, the head-to-tail orientation highly similar to p53 RE was 
found in MDR1 promoter, and p53 was able to bind this promoter region and suppressed MDR1 
promoter activity. Johnson et al. showed that when they replaced head-to-tail to head-to-head 
orientation MDR1 promoter suppression was reversed (Johnson et al., 2005). Consistent with 
this observation, Godar et al. also found a non-canonical binding site in CD44 promoter region, 
showing that only wild-type p53 was able to bind and repress CD44 promoter activity not DNA 
binding mutant p53 (Godar et al., 2008). 
 
1.3.3 DNA binding-independent mechanism 
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DNA binding-independent transrepression can be achieved through p53 interactions with other 
proteins, such as Sp1, NF-Y, NF-kB, TATA-binding proteins or basal transcriptional machinery. 
p53 has been shown to suppress Rb transcription through inhibition of the basal promoter 
activity already some time ago (Shiio et al., 1992). However, the detailed mechanisms how p53 
suppresses promoter activities without p53 DNA binding remain only marginally explored. It has 
been reported that in DNA binding-independent mode p53 mutants still retain interaction with 
other transcription factors. This is of particular importance because p53 point mutations within 
DNA binding domain are among the most frequent in cancer  (Oren and Rotter, 2010). 
 One of the common examples of p53 binding partner is Sp1, involved in regulation of 
several gene promoters, such as S100A6, MCL-1, hTERT, MGMT, HIV-LTR and beta-amyloid 
precursor protein (Bargonetti et al., 1997; Bocangel et al., 2009; Cuesta et al., 2009; Kroliczak 
et al., 2008; Pietrzak and Puzianowska-Kuznicka, 2008; Xu et al., 2000). In addition, DNA 
binding domain of Sp1 is known to interact with C-terminal of p53 (Koutsodontis et al., 2005), 
suggesting that p53-Sp1 interaction might affect the ability of Sp1 DNA binding. Consistent with 
this possibility, in vitro gel shift assay and chromatin immunoprecipitation experiments showed 
that p53 was able to reduce Sp1 DNA binding on its binding site of promoter regions in these 
genes (Bargonetti et al., 1997; Bocangel et al., 2009; Cuesta et al., 2009; Kroliczak et al., 2008; 
Pietrzak and Puzianowska-Kuznicka, 2008; Xu et al., 2000).  
Notably, in both p53 DNA binding-dependent and -independent mechanism, Sp1 is 
involved in p53-mediated transcriptional repression. It is intriguing that genome-wide approach 
to identify p53 REs also indicated that potential Sp1-binding sequences were highly enriched in 
the vicinity of p53-binding sites (Smeenk et al., 2008). However, detailed mechanisms such as 
whether p53 activates or repress through p53 DNA promoter binding and whether p53 would 
12 
 
affect Sp1 DNA binding should be empirically tested and confirmed. Since presence of cofactor 
sites and the p53-RE occlusion by nucleosomes or other proteins may affect the role of p53 and 
make p53 RE as a nonfunctional, it should be interpreted in a cell-context dependent manner 
(Riley et al., 2008).  
 
1.4  New p53 role as  regulator  of  cell motility and invasion 
 
Metastasis is responsible for most of cancer-associated mortality. It has been thought that a 
cancer cell from a primary tumor undergoes sequential steps : intravasation, extravasation and 
colonization (Chaffer and Weinberg, 2011). For the initiation of metastatic process, first of all 
cancer cells should acquire the ability to migrate and invade. As Hanahan and Weinberg 
recently revised hallmarks of cancer : (1) sustaining proliferative signaling, (2) evading growth 
suppressors, (3) avoiding immune destruction, (4) enabling replicative immortality, (5) tumor 
promoting inflammation, (6) inducing angiogenesis, (7) genome instability, (8) resisting cell 
death, (9) deregulating cellular energetics, and (10) activating invasion and metastasis 
(Hanahan and Weinberg, 2011), tissue invasion is one of the important hallmark of cancer. On 
the other hand, some hallmarks of cancer such as sustaining proliferative signaling, evading 
growth suppressors, enabling replicative immortality, angiogenesis and resisting cell death 
could also be characteristics of benign tumors (Lazebnik, 2010). Therefore, invading ability of 
cells might be the most important characteristic of cancer malignancies.  
p53 has been thought to suppress carcinogenesis by regulating proliferation, apoptosis, 
senescence, angiogenesis and DNA repair (Zilfou and Lowe, 2009). However, the role of wild-
type p53 in cell motility and invasion has not been studied in depth. It has been observed that 
wild-type p53 expression inhibits cell migration along with morphological alterations and actin 
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cytoskeleton changes (Alexandrova et al., 2000). Although detailed molecular mechanism 
remains elusive, it has been proposed that p53 regulates Rho family of small GTPase signaling, 
thereby controlling actin cytoskeletal organization and migration (Gadea et al., 2007; Gadea et 
al., 2002; Gadea et al., 2004). Members of this family include Rac, Cdc42 and Rho, controlling 
actin dynamics and cytoskeletal changes. However, a question whether this signaling 
represents the sole mechanism by p53 loss results in altered migration remains unanswered 
(reviewed in (Muller et al., 2011; Roger et al., 2006)). In addition, miR-34, a downstream target 
of p53 is known to downregulate Met, a receptor protein tyrosine kinase, which has been found 
to be overexpressed in a broad variety of human malignancies and is implicated in cell motility, 
invasion and metastasis (Birchmeier et al., 2003; He et al., 2007). While it is possible that p53 
indirectly downregulates MET expression through miR-34, Met promoter has been shown to be 
activated by p53 (Seol et al., 1999). However, no studies directly linking miR-34 and/or p53 to 
regulation of MET-dependent motility has been reported so far.  
At the same time, it has been reported that some gain-of-function p53 mutants, but not 
wild-type p53, may drive cell motility and invasion by promoting integrin recycling (Muller et al., 
2009), by forming a complex with Smad to oppose p63-mediated control of putative metastasis 
suppressors Sharp-1 and cyclin G2 (Adorno et al., 2009) or by stabilizing the invasion 
facilitateor Slug (Wang et al., 2009b). Thus, it remains unclear whether wild-type p53 plays an 
important role in regulation of cell motility and invasion. 
 
1.5  iPS cells reprogramming, p53 and miR-34 
 
Utilizing stem cells for therapeutic purposes has been of interest due to its ability to self-renew 
and differentiate into several lineages of cell types. However, ethical issues related to obtaining 
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and use of human embryonic stem cells and limited capacity of self-renewal and differentiation 
of adult stem cells create critical hurdles for their therapeutic use. One of promising resolutions 
is to utilize induced pluripotent stem (iPS) cells. iPS cells have been generated from somatic 
cells by introducing four factors (Oct-4, Klf-4, Sox-2 and c-Myc) by Yamanaka group (Takahashi 
and Yamanaka, 2006). Since iPS cells are highly similar to embryonic stem cells and also it is 
possible to generate patient-specific iPS cells, potential for therapeutic applications of such cells 
is very high, albeit the safety issue on teratoma formation of iPS cells and the difference in 
epigenetic status has to be solved. Since some of Yamanaka's factors, particularly c-Myc and 
Klf4 are known oncogenes, numerous efforts to reduce the number of required factors and 
facilitate reprogramming efficiency were undertaken (Reviewed in (Wu and Hochedlinger, 
2011)). It was shown that c-Myc improves iPS cell reprogramming process by facilitating cell 
proliferation but can be dispensable for reprogramming process (Wernig et al., 2008). More 
importantly, Wernig et al. showed that c-Myc-free iPS-derived chimera did not have enhanced 
tumor formation. In addition, in order to facilitate reprogramming and reduce the potential risk of 
virally-induced tumor formation, a number of approaches based on virus-free or vector-free 
reprogramming has been introduced (Kaji et al., 2009; Kim et al., 2009; Okita et al., 2008; 
Soldner et al., 2009; Stadtfeld et al., 2008; Yu et al., 2009). Moreover, iPS cells have been 
derived at increased efficiencies from easily accessible human cell types suitable  for disease 
modeling, drug screening and potentially cell therapy in the future (Aasen et al., 2008; Haase et 
al., 2009; Kunisato et al., 2011; Loh et al., 2009; Lowry et al., 2008). By now, a number of 
additional iPS cell factors, such as Nanog, Lin28, Tbx3, ESRRB, UTF1, Sall4 as well as miR-
291-3p, miR-294 and miR-295 have been reported to enhance reprogramming efficiency 
(Reviewed in (Judson et al., 2009; Okita and Yamanaka, 2010). Most recently, miR-302 and 
miR-372 have been shown to dramatically promote reprogramming efficiency (Subramanyam et 
al., 2011), and surprisingly even a single miRNA, miR-302 was able to reprogram human hair 
follicle cells to iPS cells (Lin et al., 2011). 
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One of the interesting factors able to improve iPS cell reprogramming efficiency is p53. 
In 2009, number of reports showed that loss of p53 led to a significant increase of iPS cell 
reprogramming efficiency by getting rid of senescence barrier that somatic cells encounter 
during reprogramming process (Hanna et al., 2009; Hong et al., 2009; Kawamura et al., 2009; Li 
et al., 2009; Marion et al., 2009; Utikal et al., 2009). Hanna et al. reported that iPS cell 
reprogramming is a stochastic process and loss of p53 improves reprogramming efficiency 
mainly through accelerating cell proliferation. To  the contrary to p53 deficiency effects, Nanog 
expression accelerated iPS cell reprogramming in a predominantly cell-division-rate-
independent manner (Hanna et al., 2009). Thus, iPS cell reprogramming could be boosted 
either by controlling proliferation or affecting the reprogramming process itself. At the same time, 
there have been several lines of evidences that p53 may be able to directly regulate important 
stem cell marker gene expression and characteristics of stem cells. First, p53 regulates Oct-4 
and Nanog expression (Lin et al., 2005; Qin et al., 2007). Second, p53 activation by nutlin 
induces rapid differentiation of embryonic stem cells (Maimets et al., 2008). Although the effect 
of p53 loss on iPS cell reprogramming may be largely through proliferation-dependent manner, 
it is still possible that p53 directly affect reprogramming process itself at least in part. Therefore, 
it is necessary to further dissect the precise role of p53 downstream targets in iPS cell 
reprogramming process. Since c-Myc is a validated target of miR-34 family, a direct target of 
p53 (Christoffersen et al., 2010; Kong et al., 2008; Lujambio et al., 2008), it is logical to test the 
role of miR-34 in iPS cell reprogramming process. 
 
1.6 Concluding remarks and project overview 
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Recent identification of p53/miR-34 regulatory network and its involvement in a number of 
human cancers opens an opportunity to search for new mechanisms suitable for development 
of diagnostic, prognostic and therapeutic approaches. High grade serous adenocarcinoma, the 
most common subtype of EOC, is characterized by frequent p53 mutations, fast progression 
and the poorest prognosis. Therefore, it is reasonable to explore the role of miR-34 family in 
epithelial ovarian carcinogenesis. In Chapter 2, we screened miR-34 expression level in a panel 
of EOC  specimens, and found  frequent downregulation of miR-34, which is mostly associated 
with p53 mutation but may also occur due to promoter CpG island methylation or copy number 
variations. Further demonstrating the important role of miR-34 in EOC, we showed that miR-34 
family suppresses cell proliferation, migration and invasion of neoplastic cells. We also 
demonstrated that miR-34-mediated control of cell motility and invasion is likely to occur via 
regulation of MET, a shared target of miR-34 family. Importantly, our experimental findings were 
consistent with identification of inverse correlation between MET and miR-34a expression in 
ovarian cancer patient specimens. In Chapter 3, we further dissected p53/miR-34/MET pathway 
in primary OSE. This system is of particular value because p53 mutations are frequent early, 
likely initiating, events during epithelial ovarian carcinogenesis. Using this model we have 
shown that p53 plays an important role in regulation of OSE cell motility and invasion. Our 
finding suggests that early genetic alterations, such as p53 mutation, may predetermine 
aggressive cancer traits such as cell migration and invasion. Furthermore, our observation that 
increased motility and invasion is highly dependent on MET expression supports MET targeting 
approach as promising cancer therapeutics. In our work we also determined that in addition to 
miR-34 mediated regulation of MET, p53 regulates MET in miR-34-independent manner, 
through inhibition of Sp1 DNA binding to MET promoter. Since mutant p53 proteins preserve 
some binding to SP1, these findings provide mechanistical explanation for the poorest 
prognosis of patients with p53 null cancer, in which both miR-34 dependent and independent 
pathways of MET downregulation by p53 are completely inactive. Finally, in Chapter 4, we 
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describe generation of mice with conditional and conventional knockout of mir-34a alone as well 
as those with entire mir-34 family. Newly developed mir-34 conditional knock-out mice allowed 
us to further confirm miR-34-independent pathway of p53 on MET regulation (described in 
Chapter 3) and test iPS cell reprogramming efficiency. Characterization of mir-34 family 
deficient mice revealed accelerated thymic aplasia and splenic hypoplasia and/or aplasia, 
suggesting potential roles in hematopoietic system development. Mouse models combined with 
tissue-specific or inducible Cre expression system will allow us direct genetic testing of miR-34 
tumor suppressive functions as well as to establish the biological roles of these highly 
evolutionary conserved miRNAs during entire mouse ontogenesis.  
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CHAPTER 2 
 
FREQUENT DOWNREGULATION OF MIR-34 FAMILY IN HUMAN OVARIAN CANCERS* 
 
2.1 Abstract 
 
The miR-34 family is directly transactivated by tumor suppressor p53, which is frequently 
mutated in human epithelial ovarian cancer (EOC). We hypothesized that miR-34 expression 
would be decreased in EOC and that reconstituted miR-34 expression might reduce cell 
proliferation and invasion of EOC cells. miR-34 expression was determined by quantitative 
reverse transcription-PCR and in situ hybridization in a panel of 83 human EOC samples. 
Functional characterization of miR-34 was accomplished by reconstitution of miR-34 expression 
in EOC cells with synthetic pre-miR molecules followed by determining changes in proliferation, 
apoptosis, and invasion. miR-34a expression is decreased in 100%, and miR-34b*/c in 72%, of 
EOC with a p53 mutation, whereas miR-34a is also downregulated in 93% of tumors with wild-
type p53. Furthermore, expression of miR-34b*/c is significantly reduced in stage IV tumors 
compared with stage III (P=0.0171 and P=0.0029, respectively). Additionally, we observed 
promoter methylation and copy number variations at miR-34. In situ hybridization showed that 
miR-34a expression is inversely correlated with MET immunohistochemical staining, consistent 
with translational inhibition by miR-34a. Finally, miR-34 reconstitution experiments in p53 
mutant EOC cells resulted in reduced proliferation, motility, and invasion, the latter of which was 
dependent on MET expression. Our work suggests that miR-34 family plays an important role in 
                                                            
* Previously published as ¶Corney and ¶Hwang et al., (2010). Clinical Cancer Research. 16 (4): 1119-
1128. ¶ Equal contribution. 
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EOC pathogenesis and reduced expression of miR-34b*/c may be particularly important for 
progression to the most advanced stages. Part of miR-34 effects on motility and invasion may 
be explained by regulation of MET, which is frequently overexpressed in EOC. 
 
2.2  Introduction 
 
Ovarian cancer is the most deadly malignancy and will lead to ∼14,000 deaths in the United 
States in 2010 (Jemal et al., 2010). Although survival has increased slightly over the past 25 
years, 5-year survival remains below 50%. A major factor for low survival is our poor 
understanding of the initiating events that lead to ovarian cancer and how the disease 
progresses. Due to asymptomatic development and few screening options, ∼70% of women 
present at late stages of carcinogenesis. At an advanced stage, treatment options are severely 
limited, with palliative treatment most often administered in the form of debulking surgery and 
paclitaxel- and platinum-based therapeutics. However, work over the past decade using human 
cancer samples and mouse models have revealed new insights into the molecular basis of 
ovarian cancer, particularly its most common form epithelial ovarian cancer (EOC). For example, 
it is well established that >50% of highgrade serous-type EOCs contain p53 mutations and 
alterations in the RB pathway (reviewed in (Bast et al., 2009) and (Corney et al., 2008)). 
Consistently, conditional inactivation of p53 and Rb in the mouse ovarian surface epithelium 
(OSE) leads to development of poorly differentiated serous ovarian adenocarcinomas (Flesken-
Nikitin et al., 2003), whereas K-Ras, Pten, and Wnt/β-catenin are implicated in carcinogenesis 
of the endometrioid EOC subtype (Dinulescu et al., 2005; Wu et al., 2007). 
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In recent years, the involvement of small noncoding RNAs, called microRNAs (miRNA), 
in cancers of many types has become unambiguous, including ovarian cancer (Iorio et al., 2007; 
Zhang et al., 2008). Although the precise roles they play during carcinogenesis are still being 
dissected, it is clear that miRNAs can act as tumor suppressors and oncogenes by regulating 
processes such as proliferation and the cell cycle, apoptosis, invasion, and metastasis 
(reviewed in (Esquela-Kerscher and Slack, 2006)). miRNAs have been found to be dysregulated 
in cancer by DNA copy number changes and epigenetic alterations, altered processing by the 
miRNA biogenesis machinery, and through altered transcriptional activation. In particular, the 
transcription factor and tumor suppressor p53 has been independently shown by several 
laboratories to directly transactivate genes of the miR-34 family, which is composed of three 
members (Bommer et al., 2007; Chang et al., 2007; Corney et al., 2007; He et al., 2007; Raver-
Shapira et al., 2007; Tarasov et al., 2007). The gene encoding miR-34a is located on human 
chromosome 1p36, whereas miR-34b and miR-34c are cotranscribed from one transcription unit 
on chromosome 11q23. The miR-34 family downregulates numerous important regulatory 
proteins and thereby presumably mediates tumor suppression (reviewed in (Hermeking, 2007)). 
Previously, we have shown that conditional inactivation of p53 results in miR-34 downregulation 
in mouse OSE (Corney et al., 2007). To evaluate the potential roles of miR-34 family in human 
EOC, we have determined their expression level in a panel of 83 cancer tissues and found that 
miR-34 expression is frequently decreased in EOC and is associated with metastatic clinical 
stage and increased expression of receptor protein tyrosine kinase MET. Furthermore, 
reconstitution of miR-34 expression in EOC cells leads to reduced proliferation and invasion as 
well as decreased MET levels.  
 
2.3 Material and methods 
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Clinical samples. Informed consent was obtained from patients undergoing surgery for ovarian 
cancer at Fox Chase Cancer Center (Philadelphia, PA) and M.D. Anderson Cancer Center 
(Houston, TX). Sample collection was done after approval by an Institutional Review Board, and 
a portion of tumor tissue not required for diagnostic purposes was snap frozen in liquid nitrogen 
and stored at −80°C. Surgical evaluation was used to determine clinical stage and presence of 
metastases, whereas histopathologic analysis by gynecologic pathologists was done to assess 
cancer type and subtype. Only tumors found to contain over 70% tumor cells were used in the 
study, and tissue sample and clinical data were available for 83 patients (Table 2.1). Additional 
formalin-fixed, paraffin-embedded specimens were obtained from New York-Presbyterian 
Hospital/Weill Cornell Medical Center (New York, NY). 
 
miR-34 nomenclature. miRNA nomenclature has recently been revised such that the miR-34b 
sequence has been renamed miR-34b* (i.e., the passenger strand; (Landgraf et al., 2007)). 
Nevertheless, “star” or passenger strands of the miRNA duplex have previously been shown to 
be biologically important (e.g., miR-199a* and miR-10*; (Migliore et al., 2008; Stark et al., 2007)). 
Although both miR-34b strands are likely to be functional, the miR-34b strand is not predicted to 
bind the 3′-untranslated region of MET and our studies have therefore focused on the miR-34b* 
strand. It is worth noting that our quantitative reverse transcription-PCR (qRT-PCR) data show 
that both strands are present at equal quantities and are highly correlated (Figure 2.2); they 
therefore might be renamed miR-34b-3p and miR-34b-5p, respectively, consistent with mouse 
miR-34b nomenclature.  
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p53 mutation screening. The IARC protocol was followed for p53 mutation screening. DNA was 
isolated by DNeasy Mini kit (Qiagen), and exons 4 to 11, including splice junctions, were 
amplified by PCR and sequenced with both forward and reverse primers (Table 2.2). In the case 
sequencing data were unclear, T-vector cloning was done, and three clones were sequenced by 
T7 and SP6 primers.  
 
Quantitative reverse transcription-PCR. Total RNA was isolated using mirVana miRNA Isolation 
kit (Ambion) according to the manufacturer's protocol, and RNA concentration and purity were 
determined by NanoDrop analysis. Stem-loop qRT-PCR for mature miR-34 and miR-199a* 
miRNAs was done as previously described (Chen et al., 2005). For MET qRT-PCR, cDNA was 
prepared from 100 ng total RNA using SuperScript III (Invitrogen) and amplified with Taqman 
primer/probes. All PCRs were done in triplicate on an ABI 7500 Real-Time PCR System 
(Applied Biosystems, Inc.), and miRNA and mRNA expression was normalized to RNU6B and 
GAPDH, respectively, using the 2−ΔΔCt method (Livak and Schmittgen, 2001). 
 
MET immunohistochemistry. Paraffin sections of formalinfixed tissue were stained according to 
modified avidin-biotinperoxidase technique (Nikitin and Lee, 1996). The antibody used for 
detection of MET was CVD13 from Zymed Laboratories (dilution, 1:200).  
 
In situ hybridization. Detection of miR-34 in a panel of serous adenocarcinomas was done by 
the protocol adapted from Nelson et al. (Nelson et al., 2006). To prevent the loss of miRNAs, we 
additionally applied 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC) fixation as described 
by Pena et al. (Pena et al., 2009). In brief, 4-μm-thick sections of formalin fixed, paraffin-
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embedded material were deparaffinized, rehydrated, and fixed with EDC. After 1-h 
prehybridization, a digoxigenin (DIG)–labeled locked nucleic acid (LNA) probe (Exiqon) was 
hybridized to proteinase K–treated sections at 56°C for 16 h. Slides were then incubated with 
anti-DIG-AP antibody (Roche), and miRNA expression was detected by nitroblue tetrazolium/5-
bromo-4-chloro-3-indolyl phosphate method. Methyl green was used for nucleic counterstaining. 
 
Quantitative PCR. For copy number variation analysis, DNA was isolated with a DNeasy DNA 
mini kit (Qiagen, Valencia, CA) and 60 ng DNA amplified with custom TaqMan real time primers 
and probes that were designed to amplify across the mir-34a locus. Copy number was 
calculated by normalizing to LINE1 retrotransposon gene copy number, which is maintained at 
relatively constant levels in neoplastic and normal tissues (Kuo et al., 2009; Wang et al., 2002), 
using the 2- ΔΔCt method (Livak and Schmittgen, 2001). Primer sequences are given in Table 2.2. 
A total of 30 serous, 1 mucinous and 2 tumors of undetermined histology with clinical 
characteristics similar to the entire cohort were analyzed. Samples Pooled human placental 
DNA served as a wild type control (Bioline, Taunton, MA). 
 
Methylation-specific PCR analysis. Genomic DNA isolated as described above was treated with 
bisulfite using the EZ DNA methylation kit (Zymo Research, Orange, CA). A total of 27 serous, 1 
mucinous and 2 undetermined EOC tumors with clinical characteristics similar to the entire 
cohort were analyzed. The modified DNA was eluted with a final volume of 16 μl, and 1 μl to 2 μl 
were used for the methylation specific polymerase chain reactions (MSP). In case of mir-34a, 
amplification conditions were 5 min at 95°C; 2 cycles of 20 sec at 95°C, 30 sec at 68°C, and 30 
sec at 72°C; followed by 2 cycles with 66°C annealing temperature, then 34 cycles with 65°C 
annealing temperature and a 4 min final extension at 72°C. For mir-34b*/c, amplification 
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conditions were 37 cycles of 20 sec at 95°C, 30 sec at 61°C and 30 sec at 72°C, 4 minutes final 
extension. Primers were used were previously reported (Lodygin et al., 2008; Lujambio et al., 
2008) and are listed in Table 2.2. PCR products were separated by electrophoresis on an 8% 
polyacrylamide gel and band intensities visually scored. 
 
Cell culture experiments. Human p53 mutant ovarian adenocarcinoma cell line SKOV-3 was 
obtained from the American Type Culture Collection and maintained according to the supplier’s 
directions. For proliferation and apoptosis analysis, cells were seeded in triplicate in 24-well 
plates and the next day transfected with Pre-miR synthetic miRNA molecules (Ambion, Austin, 
TX) using Lipofectamine 2000 (Invitrogen, Carlsbad, CA). Proliferation was assessed by BrdU 
incorporation and apoptosis assessed by cleaved caspase-3 staining 48 hours posttransfection 
as previously described (Nikitin and Lee, 1996; Zhou et al., 2006). For the apoptosis assay, 
cells were treated with 5 μM camptothecin for 17 hours to induce apoptosis. Invasion assays 
were performed in a chamber containing an 8 μm pore-size PET membrane coated with a 
uniform layer of BD Matrigel™ Basement Membrane (BD Bioscience, San Jose, CA). For MET 
knock down experiments, 2 μmol/mL of MET siRNA (sc-29397, Santa Cruz, Santa Cruz, CA) 
was transfected. 24 hours after transfection, 5 x 103 SKOV-3 cells per each well were seeded in 
a control insert or Matrigel insert in serum free media and translocated toward complete growth 
media containing 20 ng/μl hepatocyte growth factor (HGF). 20 hours after additional culture, 
invading cells were stained by Multiple Staining Solution (Polysciences, Inc., Warrington, PA) 
and counted under the microscope. All experiments were performed in triplicate and three 
different fields of each well were counted. 
 
Western blotting. Cells were lysed with RIPA buffer (25mM Tris, pH 8.2, 50mM NaCl, 0.1% SDS, 
0.5% Nonidet P-40, 0.5% deoxycholate) containing protease inhibitor cocktail (Roche, 
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Indianapolis, IN). Lysates were resolved by 8% SDS-PAGE, transferred to PVDF membrane, 
and probed with antibodies against MET (clone C-28, Santa Cruz, Santa Cruz, CA), CDK4 
(clone C-22, Santa Cruz, Santa Cruz, CA) and GAPDH (clone 6C5, Advanced Immunochemical, 
Long Beach, CA). 
 
Statistical analysis. Statistical tests used were two-sided Student's t tests, with Welch's 
correction for unequal variance, where appropriate, using InStat 3.05 and Prism 4.03 software 
(GraphPad, Inc.). 
 
2.4 Results 
 
2.4.1 miR-34 expression is reduced in EOC and is correlated with metastatic stage. 
  
To determine miR-34 family expression in EOC, we isolated total RNA from 83 EOC samples 
and compared expression levels to that in six wild-type OSE primary cell samples (Table 2.1). 
We observed significantly reduced expression for all three family members in EOC compared 
with wild-type (Figure 2.1A), with miR-34a most significantly reduced by 21.2-fold (P < 0.0001), 
whereas miR-34b* and miR-34c were reduced by 2.3-fold (P = 0.0172) and 3.4-fold (P = 
0.0002), respectively. It has been recently reported that Drosha and Dicer expression is 
deregulated in EOC (8, 25). To test whether alteration in miR-34 expression can be explained 
by Drosha/Dicer-mediated global changes in miRNA processing, we determined miR-199a* 
expression, which is deregulated in EOC (Iorio et al., 2007; Yang et al., 2008). miR-199a* 
expression seems to be elevated, although this is not statistically significant (Figure 2.3). No  
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Table 2.1 Characteristics of 83 patients with EOC 
Characteristics  Value 
   
Age (y)   
  Mean  60.8 
  Range  28-87 
Race (%)   
  White  64 (77.1) 
  African American  5 (6) 
  Other non-white  6 (7.2) 
  Unknown  2 (2.4) 
Tumor stage (%)   
  I  2 (2.4) 
  II  4 (4.8) 
  III  46 (55.4) 
   IV  18 (21.7) 
  TX  13 (15.7) 
Histology (%)   
  Serous  62 (74.7) 
  Mucinous  2 (2.4) 
  Endometrioid  3 (3.6) 
  Clear cell  1 (1.2) 
  Adenocarcinoma, NOS/undifferentiated  4 (4.8) 
  Mixed  11 (13.3) 
Abbreviation : NOS, not otherwise specified  
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Table 2.2 Sequences for primers used in this study 
Gene  Forward primer  Reverse primer  Probe  
miR-34a  AGTGTCTTAGCTGGTTGTTGTG
A  
GCAGCACTTCTAGGGCAGTAT  TTGCTGATTGCTTCCTT
ACTATTGC  
LINE1  GCTCCTGAATGACTACTGGGTA
CA  
GTGTCTTTGTTCTCGTTGGTTTCAA ACGAAATGAAGGCAGA
AATAAA  
p53  Exon 4  TGCTCTTTTCACCCATCTAC  ATACGGCCAGGCATTGAAGT  N/A  
Exon 5  TTCAACTCTGTCTCCTTCCT  CAGCCCTGTCGTCTCTCCAG  N/A  
Exon 6  GCCTCTGATTCCTCACTGAT  TTAACCCCTCCTCCCAGAGA  N/A  
Exon 7  AGGCGCACTGGCCTCATCTT  TGTGCAGGGTGGCAAGTGGC  N/A  
Exon 8/9  TTGGGAGTAGATGGAGCCT  AGTGTTAGACTGGAAACTTT  N/A  
Exon 10  CAATTGTAACTTGAACCATC  GGATGAGAATGGAATCCTAT  N/A  
Exon 11  AGACCCTCTCACTCATGTGA  TGACGCACACCTATTGCAAG  N/A  
miR-34a methylated  GGTTTTGGGTAGGCGCGTTTC  TCCTCATCCCCTTCACCGCCG  N/A  
miR-34a unmethylated  IIGGTTTTGGGTAGGTGTGTTTT  AATCCTCATCCCCTTCACCACCA  N/A  
miR-34b*/c methylated  TTTAGTTACGCGTGTTGTGC  ACTACAACTCCCGAACGATC  N/A  
miR-34b*/c unmethylated  TGGTTTAGTTATGTGTGTTGTGT CAACTACAACTCCCAAACAATCC  N/A  
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Figure 2.1 miR-34 is downregulated in EOC and associated with metastatic clinical stage. 
A. qRT-PCR analysis reveals significantly reduced miR-34a, miR-34b* and miR-34c expression 
in a panel of EOC samples (n=83; O) relative to normal OSE samples (n=6; ∆) (P<0.0001, 
P=0.0172 and P=0.0022, respectively). B. Ovarian cancer stage was determined by surgical 
evaluation during cryoreduction/debulking surgery. miR-34a, miR-34b* and miR-34c expression 
is shown for stages 1 and 2 combined (n=6; ∆), stage 3 (n= 46; O) and stage 4 (n= 18; □). miR-
34b* and miR-34c expression is significantly decreased in stage 4 (distant metastasis) 
compared to stage 3 (localized to peritoneum; P=0.0171 and 0.0029, respectively). C. 
Adenocarcinomas (serous type, n=26) and wild type OSE samples (n=6) were analyzed for p53 
mutational status by direct sequencing and correlated with miR-34 expression. While both p53 
wild type (WT; O) and p53 mutant (Mut; □) EOC samples show significantly reduced miR-34a 
expression compared to wild type OSE (N; ∆), EOC samples with mutant p53 demonstrate most 
downregulated expression for miR-34a, miR-34b* and miR-34c (P=0.0012, 0.0285 and 0.0216, 
respectively). Bars, SD. Kindly provided by Dr. David Corney. 
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significant differences in expression of miR-34 family members were detected among different 
histologic types of EOC, with an exception of significantly reduced miR-34a expression in 
endometrioid type as compared with serous adenocarcinoma (Figure 2.4). 
Tumor staging is linked to survival, with stage III tumors having tumor cell dissemination 
in the peritoneum, whereas stage IV tumors have distant metastasis, commonly to liver, and is 
indicative of poor prognosis. We compared gene expression in stage III and IV tumors and 
observed significantly reduced miR-34b* and miR-34c expression in stage IV tumors (P = 
0.0171 and P = 0.0033, respectively; Figure 2.1B), suggesting that miR-34b* and miR-34c may 
be involved in metastatic progression. Interestingly, however, change in miR-34a expression 
was not statistically significant (P = 0.2574). 
 
2.4.2 Decreased miR-34 expression is associated with p53 mutation.  
 
Mutation of p53 is a common event in many human cancers but is particularly common in high-
grade serous EOC (Corney et al., 2008). We therefore took a subset of our serous EOC 
samples (n = 26) and sequenced p53 exons 4 to 11, where >99% of p53 mutations are located 
(Table 2.3). We have found that although miR-34a expression is reduced in both samples with 
wild-type or mutant p53, patients with mutant p53 show significantly lower expression of all miR-
34 family members than patients with wild-type p53 (P = 0.0012, 0.0285, and 0.0216 for miR-
34a, miR-34b*, and miR-34c, respectively; Figure 2.1C).  
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Table 2.3 p53 mutation status of human samples 
Case no.  Mutation 
type  
exon  codon  Change  Wild-type  Mutated  Wild-type 
AA  
Mutated 
AA  
OvCa 1  Wild-type  
OvCa 2  Wild-type  
OvCa 6  Wild-type  
OvCa 11  Wild-type  
OvCa 12  Wild-type  
OvCa 21  Wild-type  
OvCa 24  Wild-type  
OvCa 27  Wild-type  
OvCa 28  Wild-type  
OvCa 31  Wild-type  
OvCa 4  Missense  7  237  G>A  ATG  ATA  Met  Ile  
OvCa 7  Missense  6/7  220/229  A>G / T>C  TAT/TGT  TGT/CGT  Tyr/Cys  Cys/Arg  
OvCa 8  Missense  5  176  G>T  TGC  TTC  Cys  Phe  
OvCa 10  Missense  11  375  A>G  CAG  CGG  Gln  Arg  
OvCa 14  Missense  7  244  G>A  GGC  GAC  Gly  Asp  
OvCa 15  Missense  7  237  G>T  ATG  ATT  Met  Ile  
OvCa 17  Missense  8  286  G>A  GAA  AAA  Glu  Lys  
OvCa 18  Missense  5  151  C>T  CCC  TCC  Pro  Ser  
OvCa 25  Missense  7  248  G>A  CGG  CAG  Arg  Glu  
OvCa 30  Missense  11  385  T>C  TTC  TCC  Phe  Ser  
OvCa 32  Missense  7  241  C>G  TCC  TGC  Ser  Cys  
OvCa 13  Nonsense  5  144  C>T  CAG  TAG  Gln  STOP  
OvCa 33  Nonsense  4  107  C>A  TAC  TAA  Tyr  STOP  
OvCa 16  Insertion  5  169  + T  ATG  
OvCa 22  Insertion  4  99  + C  TCC  
OvCa 34  Deletion  7  241  - T  TCC  
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2.4.3 Regulation of miR-34 by promoter methylation and copy number alterations.  
 
Promoters of both mir-34a and mir-34b*/c are located in CpG islands, and methylation has been 
reported to regulate miR-34a expression in several cancer cell lines and primary prostate 
tumors and melanomas, whereas miR-34b*/c expression in colorectal cancer is also 
epigenetically regulated (Lodygin et al., 2008; Toyota et al., 2008). Such methylation has not 
been reported in ovarian cancer, so we set out to determine the frequency of such methylation 
by methylation-specific PCR analysis. Methylation at the mir-34a and mir-34b*/c loci was 
observed in 27% (8 of 30) and 47% (14 of 30) of EOC samples, respectively (Figure 2.5A). All 
samples (8 of 8) with mir-34a methylation show reduced miR-34a expression, whereas 57% (8 
of 14) of samples with methylation at mir-34b*/c show reduced miR-34b*/c expression. 
Classification of samples based on p53 mutation status revealed that 21% (3 of 14) and 
50% (7 of 14) of mutant p53 samples show promoter methylation at mir-34a and mir-34b*/c, 
respectively, whereas for samples with wild-type p53, 38% (5 of 13) and 46% (6 of 13) show 
methylation, respectively.  
We next raised the question of whether loss of heterozygosity or copy number 
alterations could be responsible for reduced miR-34a expression and designed custom Taqman 
primer and probes to amplify the mir-34a locus in a qPCR assay. Reduced copy number at the 
mir-34a locus was observed in 39% (13 of 33) of EOC samples (Figure 2.5B), of which 92% (12 
of 13) had reduced miR-34a expression. Three of these 12 samples (25%) with reduced mir-34a 
copy number and expression showed no p53 mutation or promoter methylation. Taken together, 
reduced miR-34a expression is associated with p53 mutation, mir-34a promoter methylation, 
and/or copy number variation in 82% (27 of 33) of EOC samples. 
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2.4.4 miR-34 and MET expression in EOC paraffin sections.  
 
To explore miR-34 expression in EOC tissue, we did miRNA in situ hybridization with paraffin-
embedded tissue sections of human ovarian cancer. In the case of miR-34a probe, we observed 
positive signal in cytoplasm compared with control probe, whereas U6 small nuclear RNA was 
exclusively expressed in the nucleus as expected (Figure 2.6A-C). We tested a total of 21 cases 
of serous EOC with LNA miR-34a probe. Consistent with qRT-PCR data, 85.7% (18 of 21) of 
cases have weak or undetectable miR-34a expression. 
One of the shared targets of miR-34 family is the receptor tyrosine kinase MET 
according to bioinformatic assessment and luciferase assays (He et al., 2007; Migliore et al., 
2008). Furthermore, the majority of EOCs express elevated levels of MET (Auersperg et al., 
2001). Thus, we decided to compare MET expression level in parallel sections of 17 cases with 
semiquantitative immunohistochemical analysis. EOC cases expressing moderate to strong 
miR-34a (Figure 2.6C) had a relatively weak expression of MET (Figure 2.6D). On the contrary, 
low miR-34a–expressing EOC (Figure 2.6E) had strong expression of MET (Figure 2.6F). 
Based on semiquantitative analysis, expression of miR-34a and MET had statistically significant 
inverse correlation (r = −0.5898; P = 0.0162), confirming that miR-34a might play a role in 
regulating MET expression in EOC. 
 
2.4.5 miR-34 reduces migration, invasion, and proliferation in EOC cells.  
 
To determine the role of miR-34 in human ovarian cancer, we transfected synthetic miR-34 
molecules either separately or in combination into SKOV-3, p53-null human ovarian adenocarc- 
55 
 
 
 
 
 
 
 
Figure 2.6 miR-34a expression is inversely associated with MET expression in EOC. 
Sections of formalin-fixed, paraffin-embedded human EOC specimens were hybridized with 
DIG-labeled LNA control probe (A), U6 small nuclear RNA probe (B), and miR-34a probe (C and 
E) or immunostained with MET antibody (D and F). C and D, EOC with strong miR-34a 
expression shows relatively low level of MET expression. E and F, on the contrary, EOC with 
weak miR-34a expression has strong staining for MET. Insets show high magnification of areas 
indicated with arrows. Similar structures of parallel sections (A and B, C and D, and E and F) 
are indicated with arrowheads. Methyl green and hematoxylin were used for counterstaining of 
in situ hybridization and immunostaining, respectively. Scale bar, 100 µm. Parts D and F kindly 
provided by Andres Matoso. 
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inoma cells (Figure 2.7 and 2.8). SKOV-3 cells express low endogenous levels of all three miR-
34 family members (Corney et al., 2007; Zhang et al., 2008) and are therefore well suited to test 
functions of miR-34. We transfected SKOV-3 cells with 15 nmol/L miR-34 individually or 5 
nmol/L combined and observed reduced amounts of MET protein and mRNA (Figure 2.7A and 
B). Even more significant reduction of MET levels was observed after transfection with 30 
nmol/L miR-34 (Figure 2.7C). 
The miR-34 family has been shown to reduce cell invasion in gastric and hepatocellular 
carcinoma cells, at least partially through downregulation of MET (Li et al., 2009; Migliore et al., 
2008). To examine the role of miR-34 family in invasion and motility in ovarian cancer, we did 
Transwell motility and Matrigel invasion assays with miR-34 family and/or MET small interfering 
RNA (siRNA)–transfected SKOV-3 cells. Notably, whereas MET knockdown was observed after 
MET siRNA treatment, cyclin-dependent kinase 4 (CDK4), which is another target of miR-34 
family, was not affected by MET siRNA but only after miR-34 family transfection (Figure 2.7C). 
As expected, individual miR-34 reconstitution by transfection caused significant reduction in 
motility and invasion in the presence of the MET ligand, hepatocyte growth factor (Figure 2.7D 
and E; Figure 2.8). However, when miR-34 and MET siRNA were transfected together, no 
further reduction was observed, showing that MET downregulation by miR-34 is largely 
responsible for the reduced invasion. 
Next, we asked whether miR-34 family reconstitution reduces cell proliferation because 
miR-34 family also can target cell cycle–related genes such as CDK4 (Figure 2.7C). 
Transfection of SKOV-3 cells with either 15 nmol/L miR-34a, miR-34b*, or miR-34c reduced 
proliferation by ∼30% compared with control-transfected cells (P =0.0044, 0.0042, and 0.0106, 
respectively; Figure 2.7F). We next treated cells with a combination of 5 nmol/L of each miR-34  
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Figure 2.7 miR-34 reconstitution decreases migration, invasion and proliferation in EOC 
cells. A and B. Individual miR-34 family member (15 nM) or entire miR-34 family (5 nM each) 
were transfected and statistically significant reduction in mRNA observed for each treatment 
(miR-34a, p=0.028; miR-34b*, p=0.0017; miR-34c, P=0.0022; entire miR-34 family, P=0.0020), 
although reconstitution of entire miR-34 family does not further downregulate MET expression. 
C. MET siRNA and/or indicated miR-34 precursor molecule (30 nM) were transfected in SKOV-
3 cell line. Transfected cell lysates were probed against MET, CDK4 and GAPDH in Western 
blot analysis. MET siRNA induced strong knockdown of MET protein with no effect on CDK4, 
while miR-34 downregulated CDK4 as well as MET. D and E, MET siRNA and/or miR-34 
transfection induced significant reduction of cell migration (MET siRNA, P=0.0005; miR-34a, 
P=0.0003; miR-34c, P=0.0003; MET siRNA and miR-34a, P=0.0008; MET siRNA and miR-34c, 
P=0.0003) and invasion (MET siRNA, P=0.0013; miR-34a, P=0.0009; miR-34c, P=0.0011; MET 
siRNA and miR-34a, P=0.0009; MET siRNA and miR-34c, P=0.0009). F. Quantitative 
assessment of proliferation by BrdU incorporation 48 hours after transfection of SKOV-3 cells 
with either 15 nM synthetic miR-34a, miR-34b* or miR-34c Pre-miR individually, or 5 nM of each 
Pre-miR concurrently (miR-34a, P=0.0044; miR-34b*, P=0.0042; miR-34c, P=0.0106; miR-34 in 
combination, P=0.0021). Bars, SD. Part F kindly provided by David Corney. 
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family member to determine whether additional suppression could be achieved due to sequence, 
and presumably target, differences of miR-34 family members. Although the percentage of 
proliferative cells was reduced to 20.7% (P = 0.0021, compared with control), the difference in 
reduction compared with miR-34c transfection individually was not statistically significant (P = 
0.0876). Additionally, we assessed the amount of apoptosis in miR-34–transfected cells by 
determination of cleaved caspase-3 staining (Figure 2.9). No significant change in number of 
apoptotic cells was observed in p53 mutant SKOV-3, consistent with miR-34–induced apoptosis 
being p53 dependent (Yamakuchi et al., 2008). 
 
2.5 Discussion 
 
Previously, we showed that miR-34b-5p and miR-34c expression is reduced in a p53-dependent 
manner in a mouse model of EOC, whereas others also reported reduced miR-34 expression in 
a variety of cell lines and mouse models (Bommer et al., 2007; Chang et al., 2007; Corney et al., 
2007; He et al., 2007; Raver-Shapira et al., 2007; Tarasov et al., 2007). These results led us to 
question the involvement of miR-34 in human EOC, and we show here that miR-34 family 
expression is also significantly reduced in human EOC, particularly in patients with p53 
mutations. 
Recently, the involvement of Drosha and Dicer in EOC has been reported, linking 
reduced expression of these proteins to poor outcome (Merritt et al., 2008). Yet, although 
reduced Drosha/Dicer processing might be expected to lead to globally decreased miRNA 
expression, this does not seem to account for all miRNA expression defects, given that miR-
199a* expression is modestly increased (Figure 2.3). Moreover, unlike miR-34a, miR-34b*/c 
expression is not reduced in tumors with wild-type p53. This discrepancy between miR-34a and  
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miR-34b*/c expression suggests that, in addition to shared p53-dependent transactivation, 
control mechanisms unique to miR-34a are altered in tumors with wild-type p53. Underlining 
differences between the two mir-34 loci is our observation that expression of miR-34b*/c, but not 
expression of miR-34a, is significantly associated with stage IV distant metastatic disease 
(Figure 2.1B). 
To understand the cause of these differences, we investigated the role of promoter 
methylation and copy number variations of mir-34. mir-34 promoter methylation has been 
reported in several tumor types (Lodygin et al., 2008; Toyota et al., 2008), whereas megabase 
pair deletions at chromosome 1p36 containing the mir-34a locus have been identified in seven 
low-grade serous carcinomas (Kuo et al., 2009) and in neuroblastoma (Welch et al., 2007). 
Indeed, promoter methylation was observed at mir-34a and mir-34b*/c in 27% and 47% of EOC 
samples, respectively. Furthermore, reduced mir-34a copy number was observed in 39% of 
samples. However, there was no direct correlation between methylation or copy number and 
miR-34 expression levels. There are several possible explanations that may account for these 
data. Firstly, although our p53 sequencing data identified p53 mutations with high confidence, 
mutation in genes that regulate p53 may be involved, such as MDM2, which posttranslationally 
silences p53 through ubiquitinylation (Haupt et al., 1997; Kubbutat et al., 1997), whereas p53 
may itself be epigenetically silenced (Kang et al., 2001). Secondly, many miRNAs, including 
miR-34a, have been shown by Chang et al. (Chang et al., 2008) to be suppressed by c-Myc, an 
oncogene frequently overexpressed in multiple tumor types, including EOC. Additionally, it is 
likely that additional transcription factors regulate miR-34 expression. Recently, Christoffersen 
et al. (Christoffersen et al., 2010) studied human primary hTERT-immortalized TIG3 fibroblasts 
and observed p53-independent transcription of miR-34a. Oncogene-induced senescence 
mediated through B-RAF activation induces miR-34a expression in cells treated with a p53 
siRNA or a p53 dominant-negative variant. Through chromatin immunoprecipitation experiments, 
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the authors show that the ETS oncogene family member and transcription factor ELK1 binds a 
conserved region in the mir-34a promoter. 
Clearly, future studies are required to obtain a more complete understanding of the 
regulation of miR-34 expression in both normal development and disease. However, the 
observation of B-RAF–induced miR-34a expression through oncogene-induced senescence 
raises an important question about the etiology of EOC. It has been hypothesized that low- and 
high-grade serous tumors have distinct precursor lesions (Corney et al., 2008; Singer et al., 
2005), with p53 mutations rarely found in low-grade tumors but common in high-grade tumors. 
Interestingly, and further emphasizing the differing molecular defects between the two tumor 
types, activating B-RAF mutations are found exclusively in low-grade serous EOC (Shih and 
Kurman, 2004; Singer et al., 2003). Together, this suggests that activation of miR-34a 
transcription by B-RAF/ELK1 and p53 in low-grade serous EOC induces senescence and 
prevents progression to high-grade disease. In contrast, a lack of B-RAF mutations combined 
with frequent p53 mutation in high-grade serous EOC would seem to largely eliminate miR-34 
expression, and subsequently, tumor suppression capability is lost. Additionally, whereas p53 
mutation has no effect on miR-34b*/c methylation, miR-34a methylation is more common in 
samples with wild-type p53, consistent with a requirement for diminished p53–miR-34 activity to 
progress to carcinoma. Together, these observations suggest that high-grade tumors arise from 
a population of cells with mutated p53 but wild-type B-RAF. Our data showing correlation of 
miR-34b*/c expression with metastatic disease suggest that these two miRNAs will be useful as 
a prognostic marker. This observation is in a good agreement with a recent report that low miR-
34a levels are correlated with increased probability of relapse in non–small cell lung carcinoma 
(Gallardo et al., 2009) and reinforces the importance of decreased miR-34 expression. Future 
studies based on complete follow-up data will determine if miR-34 expression correlates with 
survival of EOC patients. 
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Our functional studies of miR-34 reconstitution suggest therapeutic applications too. 
miRNAs represent attractive candidates for gene therapy approaches for several reasons. 
Computationally, individual miRNAs have been predicted to target tens or hundreds of mRNAs 
for translational repression. Indeed, one miRNA may regulate many targets. For example, in the 
case of miR-223 in neutrophils, hundreds of proteins are directly repressed, which has a 
significant effect on phenotype, despite protein repression being relatively modest (Baek et al., 
2008; Johnnidis et al., 2008). It is noteworthy that microarray experiments done after miR-34 
reconstitution in cancer cell lines revealed highly significant alterations that are clustered to 
important biological pathways (e.g., cell cycle pathway genes; (Bommer et al., 2007; He et al., 
2007)). These data suggest that reconstituted expression of a downregulated miR-34 might 
reset or otherwise induce normal function of these gene networks. 
Due to its large number of transcriptional targets, p53 has also been an attractive 
candidate for gene therapy. It was therefore disappointing that p53 gene therapy in EOC failed 
in phase II/III clinical trials (Zeimet and Marth, 2003). Yet, whereas p53 therapy may have failed 
due to p53 degradation through MDM2 and dominant-negative tetramer formation, gene therapy 
with a p53-independent miR-34 transgene under control of a strong promoter would not be 
expected to face either of these problems. Furthermore, miR-34 may be more attractive than 
p53 due to its small size, making it more amenable to packaging in viral and nonviral 
technologies. No less of importance, several EOCs do not harbor p53 mutations but express 
low levels of miR-34, which could be corrected. Thus, it would be interesting to study the 
consequence of miR-34 delivery to EOC cells with wild-type p53. However, currently 
characterized EOC cell lines carrying wild-type p53, such as the serous adenocarcinoma cell 
line A2780 and clear cell carcinoma cell line TOV-21G (He et al., 2007; Migliore et al., 2008), 
show high levels of expression of endogenous miR-34. 
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MET is one of few common targets for all three miR-34 family members. Taking into 
account that the majority of EOCs express elevated levels of MET (Auersperg et al., 2001), we 
have tested the role of all miR-34 family members in repression of MET in EOC cells by using 
Western blotting, invasion, and motility assays, finding that all three members inhibit MET. 
Small-molecule MET inhibitors are now under clinical trials for several cancers (Comoglio et al., 
2008), and Sawada et al. (Sawada et al., 2007) showed that MET siRNA could reduce adhesion, 
invasion, metastasis, and tumor burden in intraperitoneal ovarian cancer xenograft model but 
did not affect proliferation. 
On the contrary, miR-34 therapeutics may have advantages compared with siRNA 
approach because miR-34 is capable of regulating cell proliferation as well as invasion through 
targeting several target genes in addition to MET, such as MYC and E2F3. This is underscored 
by our experiment showing reduced CDK4 protein after miR-34 treatment, but not MET siRNA. 
Taken together, our data show the frequent reduction of miR-34 family expression in 
EOC and its functional properties as an inhibitor of proliferation and invasion. This miRNA family 
is therefore an attractive candidate gene for further studies aimed at better understanding of 
disease pathogenesis and development of novel therapeutic approaches. 
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CHAPTER 3 
 
WILD-TYPE P53 CONTROLS CELL MOTILITY AND INVASION BY DUAL REGULATION OF 
MET EXPRESSION * 
 
3.1 Abstract 
 
Recent observations suggest that p53 mutations are responsible not only for growth of primary 
tumors but also for their dissemination. However, mechanisms involved in p53-mediated control 
of cell motility and invasion remain poorly understood. By using the primary ovarian surface 
epithelium cell culture, we show that conditional inactivation of p53 or expression of its mutant 
forms results in overexpression of MET receptor tyrosine kinase, a crucial regulator of invasive 
growth. At the same time, cells acquire increased MET-dependent motility and invasion. Wild-
type p53 negatively regulates MET expression by two mechanisms: (1) transactivation of MET-
targeting miR-34 and (2) inhibition of SP1 binding to MET promoter. Both mechanisms are not 
functional in p53 absence, while mutant p53 proteins retain partial MET promoter suppression. 
Accordingly, MET overexpression, cell motility and invasion are particularly high in p53 null cells. 
These results identify MET as a critical effector of p53 and suggest that inhibition of MET may 
be effective anti-metastatic approach to treat cancers with p53 mutations. They also show that 
the extent of advanced cancer traits, such as invasion, may be determined by alterations in 
individual components of p53/MET regulatory network.  
 
                                                            
* Previously published as Hwang et al., Proc Natl Acad Sci U S A (2011). 108 (34): 14240-14245. 
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3.2 Introduction 
 
Transcriptional factor p53 provides integrated responses to implement cell cycle arrest, 
senescence, differentiation, inhibition of cancer metabolism or induction of the apoptotic 
cascade (Vousden and Prives, 2009). Mutations of p53 occur in about 50% of all cancers and 
result in loss of its function, either by null phenotype or dominant-negative effect. Additionally, 
some mutations result in new activities of p53, known as gain-of-function mutations (Brosh and 
Rotter, 2009). Recent observations indicate that p53 mutations affect cell motility and invasion, 
key features of metastasis (Adorno et al., 2009; Alexandrova et al., 2000; Gadea et al., 2007; 
Muller et al., 2009; Muller et al., 2011; Wang et al., 2009). Better understanding of mechanisms 
of p53-dependent effects on cell motility and invasion should lead to development of 
approaches aimed towards correction of aberrant p53 signaling not only for suppressing growth 
of primary tumors but also for preventing their dissemination.  
 A signaling conduit known to play a critical role in invasion and metastasis is the MET 
pathway (Mazzone and Comoglio, 2006). The MET proto-oncogene encodes a transmembrane 
receptor protein tyrosine kinase, whose overexpression is associated with poor prognosis in a 
broad variety of cancers (Comoglio et al., 2008; Sawada et al., 2007). Inhibition of MET 
functions has been shown to be effective in animal models and is among the most promising 
candidates for targeted therapy (Comoglio et al., 2008).  
 Previously it has been reported that MET is overexpressed in tumors of p53-deficient 
mice and in Li-Fraumeni patients (Rong et al., 1995). This observation is consistent with recent 
reports that MET represents one of the common targets for miR-34 family (Corney et al., 2010; 
He et al., 2007; Migliore et al., 2008). Genes encoding for miR-34 family have been identified as 
direct targets of p53 transactivation (reviewed in (Hermeking, 2007). At the same time, it has 
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been reported that mouse Met promoter has a putative p53 responsive element and that Met 
promoter activity is activated by p53 through DNA binding to p53 consensus sequence (Seol et 
al., 1999). Thus, the role of MET in p53-dependent invasion remains uncertain.  
 Because many cancers are genomically unstable and separation of critical alterations 
from “genetic noise” may be a daunting task in cells derived from advanced stages of the 
disease, we have used a model of conditional p53 inactivation in the primary ovarian surface 
epithelium (OSE), transformation of which leads to epithelial ovarian cancer (EOC) (Corney et 
al., 2007; Flesken-Nikitin et al., 2003). This system is highly clinically relevant, because p53 
mutations are by far the most frequent alterations in high-grade serous adenocarcinoma of the 
ovary (Ahmed et al., 2010), are detected in the stage 1 of those cancers and in adjacent 
dysplastic lesions (Berchuck et al., 1994; Leitao et al., 2004), and their presence correlates with 
metastatic potential (Bast et al., 2009). MET overexpression is also associated with poor 
prognosis of EOC patients and targeting the MET pathway has been reported to suppress EOC 
in mouse models (Sawada et al., 2007). 
 We report that MET is a critical player in p53-mediated control of motility and invasion, 
and show that such control includes miR-34-independent regulation of MET expression by p53, 
in addition to earlier described MET targeting by miR-34. Alterations in individual components of 
p53/MET regulatory network may affect the extent of cancer invasion. 
 
3.3 Methods 
 
Experimental animals. Mice with floxed copies of p53, Rb1, Met and p53 mutant allele genes 
and genotyping PCR information were described elsewhere (Huh et al., 2004; Jonkers et al., 
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2001; Marino et al., 2000; Olive et al., 2004). Z/EG reporter mice (Novak et al., 2000) were 
purchased from the Jackson Laboratory. All mice were maintained identically following 
recommendations of the Cornell Institutional Laboratory Animal Use and Care Committee. 
 
Cell culture. Primary mouse OSE cells and OSE cell lines (OSN1; p53 and Rb null, OSN2; p53 
null) were isolated and cultured as previously described (Corney et al., 2007; Flesken-Nikitin et 
al., 2003; Flesken-Nikitin et al., 2007). Human ovarian cancer cell lines SKOV-3 (p53 null), 
OVCAR-3 (p53 mutant), human lung cancer cell line NCI-H1299 (p53 null) and human colon 
cancer cell line HCT116 (p53 wild-type) were obtained from the American Type Culture 
Collection (Manassas, VA) and maintained according to the supplier's directions. Human 
ovarian cancer cell lines OVCA432 (p53 mutant) and OVCA433 (p53 wild-type) were 
maintained as described previously (Mok et al., 1995; Tsao et al., 1995). Transfection was 
performed by using lipofectamine 2000 (Invitrogen, Carlsbad, CA), and control (sc-37007) and 
p53 siRNA (sc-29436 and sc-29435 for mouse and human respectively) were purchased from 
Santa Cruz Biotechnology (Santa Cruz, CA). Mithramycin A and doxorubicin were purchased 
from Sigma, and HGF from R&D Biosystems (Minneapolis, MN). In experiments with conditional 
gene inactivation the efficiency of adenoviral infection was over 90% according to use of 
adenoviral Cre:EGFP fusion protein expression system. Cre-mediated gene excision was at 
similar levels, according to PCR genotyping (Figure 3.6B-C) and our previous experiments with 
Rosa26STOPflLacZ reporter (Flesken-Nikitin et al., 2003). 
 
Cell proliferation and senescence assays. Proliferation of OSE was assessed by BrdU 
incorporation as described elsewhere (Flesken-Nikitin et al., 2003). For detection of 
senescence-associated β-galactosidase OSE cells were fixed with 3% formaldehyde, rinsed 
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several times with PBS and incubated in staining-solution (4.2 mM citric acid, 12.5 mM sodium-
phosphate, 158 mM sodium chloride, 0.21 mM magnesium chloride, 2.21 mg/ml potassium 
ferrocyanide, 1.68 mg/ml potassium ferricyanid, 1 mg/ml X-Gal, pH 6.0) for 24 hrs at 37 °C. 
 
Conditional gene inactivation and mRNA microarray profiling studies. Primary OSE cells 
carrying conditional gene alleles were passaged 3 times and treated with recombinant 
adenoviruses essentially as described previously (Corney et al., 2007; Flesken-Nikitin et al., 
2003). Cells were collected 2 passages after infection and processed for mRNA isolation and 
assessment of mRNA profiles. Total RNA was prepared using RNeasy lipid tissue mini kit 
(Qiagen, Valencia, CA). The generation of biotin-labeled cRNA fragmentation, hybridization to 
the Affymetrix murine U74Av2 arrays (Santa Clara, CA), washing, and scanning were done 
according to Affymetrix protocols. The gene expression signals from Affymetrix GCOS software 
were normalized by scaling each GeneChip to a target signal of 500. Log ratio was calculated 
with the average value of control groups. Analysis was performed by using Significant Analysis 
of Microarrays (SAM) software (http://www-stat.stanford.edu/~tibs/SAM/) with 2 fold setting and 
1% False Discovery Rate (FDR) of genes (Tusher et al., 2001). Identified profile was visualized 
in TreeView software (http://rana.lbl.gov). 
 
Trans-infundibular administration of adenovirus, collection of histological materials and 
immunohistochemistry. All procedures were performed as described previously (Flesken-Nikitin 
et al., 2003). Double immunofluorescence staining of frozen sections was done with rabbit 
polyclonal antibody to EGFP (Clontech, Mountain View, CA, 632377, 1:100) or to rabbit 
polyclonal MET (Santa Cruz Biotechnology, Santa Cruz, CA, SP260, 1:100), followed by 
fluorescein (FITC)-conjugated anti-rabbit and rhodamine (TRITC)–conjugated anti-rabbit 
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secondary antibodies (Jackson ImmunoResearch Laboratories, 1:50). To stain cell nuclei, 
sections were incubated with a 10 µg/mL solution of 4',6-diamidino-2-phenylindole (DAPI; 
Sigma-Aldrich, St. Louis, MO) for 4 min. 
  
Wound healing, time-lapse microscopy, migration and invasion assay. For wound healing assay, 
OSE cells were infected with adenovirus and cultured in 10 cm gelatin-coated dish to 
confluence. Cells were scraped with p200 tip, and fresh medium supplemented. Digital images 
of the wound were taken at 0, 12 and 24 hours after scraping. Percentage of closed wound area 
was measured by using TScratch software (Geback et al., 2009). For the time-lapse microscopy, 
cells were grown until confluent and then partially scratched by a 2 mm wide plastic space. 
Twenty four hrs after scratching, complete culture medium were replaced with CO2-independent 
medium supplemented with 5% fetal bovine serum. Cell movements were captured using a 
camera on a microscope at 20x objective in a 37°C chamber. Image of the cells was taken 
every 15 minutes for 5 hrs for a total of 21 images. Individual cell movements were tracked by 
using Image J, Multitrack software. Migration and invasion assays were performed as described 
in (Corney et al., 2010). 
 
Quantitative real-time RT-PCR. Total RNA was isolated using Qiazol (Qiagen, Valencia, CA) 
according to manufacturer's protocol. Total RNA was reverse transcribed using SuperScript III 
(Invitrogen, Carlsbad, CA) and oligo-dT primers. The PCR reactions were done in a 30-μl 
volume in a 96-well plate using pre-developed FAM TaqMan probes (Applied Biosystems, 
Foster City, CA). Mouse and human Gapdh were used as endogenous reference control (pre-
developed TaqMan assay from Applied Biosystems). Cycling parameters were as follows: 95˚C 
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for 10 min. followed by 40 cycles of 95˚C for 15 seconds and 60˚C for 1 min. Increase in real-
time fluorescence was measured by an ABI7500 qPCR system and relative fold changes were 
calculated using the 2 -ΔΔCt method (Livak and Schmittgen, 2001). 
 
Promoter analysis. pGL2-3.1MET construct consists of 3 Kb upstream sequence and 131 bp 
5’UTR of human MET gene. pGL2-0.65MET construct consists of 653 bp upstream sequence 
including 131 bp 5’-UTR (Gambarotta et al., 1996). 0.37MET construct was cloned from -512 to 
-136 of MET 3.1 fragment. pGL2-0.27MET construct consists of 136 bp of MET upstream 
sequence and 131 bp of 5’-UTR. The corresponding human sequence of previously reported 
p53 binding site (Seol et al., 1999) in mouse Met promoter (from -289 to -256) was mutated. 
5'GGACGGACAGCACGCGAGGCAGACAGACACGTG3' sequence was changed into 
5'GGACGGACAGCACGCGAGGCAGACAGACAAAAG3'. To measure luciferase activity, cells 
were processed with the Luciferase Reporter Assay System (Promega, Madison WI) according 
to manufacturer's instructions, and 10 μl of cell lysates was used to determine reporter enzyme 
activity using Lumat LB 9501 luminometer (Berthold, Bad Wilbad, Germany). Lipofectamin 2000 
reagent (Invitrogen, Carlsbad, CA) was used for the transfection following manufacturer’s 
recommendations. pORF-hp53 was purchased from InvivoGen (San Diego, CA). Pre-miR 
miRNA precursor molecules of miR-34a, b and c, as well as control pre-miR were purchased 
from Ambion (Austin, TX). Each experiment was performed in triplicates. Luciferase activities 
were normalized to total protein concentrations. BCA method (Pierce, Rockford, IL) was applied 
for measuring protein concentrations.  
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Western blot analysis. Cell lysates were prepared using RIPA buffer (Tris-HCl 50 mM, pH 7.4; 
NP-40 1%; Na-deoxicholate 0.25%; NaCl 150 mM; EDTA 1 mM; PMSF 1 mM; Aprotinin, 
leupeptin, pepstatin: 1 μg/ml each; Na3VO4 1 mM; NaF 1 mM), separated by 12% SDS-
polyacrylamide gel electrophoresis and transferred to PVDF membrane (Millipore, Billerica, MA). 
The membrane was incubated overnight at 4˚C with antibodies to detect MET (SP 260 for 
mouse and C28 for human, Santa Cruz Biotechnology, 1:1000 dilution for both), p53 (FL 393 
from Santa Cruz Bitechnology, 1:1000 dilution), CD44 (2C5, R&D Systems, Inc., Minneapolis, 
MN), Hif-1α (H1alpha67 from NOVUS biologicals, Littleton, CO), phospho-MET (Y1234/1235 
from Cell Signaling Technology, Danvers, MA), SP1 (Millipore, Billercia, MA) and Gapdh 
(Advanced Immunohistochemical Inc.; Long Beach, CA; 1:3000 dilution) followed by incubation 
for one hr at room temperature with horseradish peroxidase-conjugated secondary antibodies 
(Santa Cruz Biotechnology, Santa Cruz, CA) and developed using chemiluminescence 
substrate (SuperSignal West Pico from Pierce; Rockford, IL). 
 
Co-immunoprecipitation. Lysates of were prepared in modified Lysis250 buffer (50 mM Tris-HCl 
pH 7.4, 100 mM NaCl, 5mM EDTA, 0.1% NP-40 100 mM). The antibodies used for 
immunoprecipitation were polyclonal anti-SP1 (Millipore, Billercia, MA), polyclonal anti-p53 
(Santa Cruz Biotechnology, Santa Cruz, CA) and monoclonal anti-p53 (Cell Signaling 
Technology, Danvers, MA). Cell extracts were incubated at 4°C overnight with 2 µg of 
corresponding antibodies, followed by incubation with 20 µl of Sepharose G bead (GammaBind 
Plus Sepharose, GE Healthcare, Niskayuna, NY) for 2 hrs at 4°C. Immunoprecipitates were 
isolated by centrifugation and followed by 5 times washing with lysis buffer. Samples were 
resuspended in the 2X sample buffer, subjected to 12% SDS-polyacrylamide gel 
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electrophoresis, transferred onto a PVDF membrane and the immunoprecipitated proteins were 
detected by Western blotting. 
 
Chromatin immunoprecipitation (ChIP). SKOV-3 cells were grown on 10 cm dishes and 
transfected with control and p53 expression vector respectively. One day after transfection, 1% 
formaldehyde was added for 10 min at 37°C to cross-link proteins to DNA. Cells were washed 
two times with ice-cold 1X PBS, scraped and lysed with SDS lysis buffer (Millipore, Billercia, MA) 
in the presence of protease inhibitors cocktail. The lysates were sonicated to shear DNA to 
lengths between 200 bp and 1000 bp. After 10 fold dilution of the sonicated cell supernatants in 
ChIP dilution buffer (Millipore, Billercia, MA) supplemented with the protease inhibitors cocktail 
(Roche, Indianapolis, IN), immunoprecipitations were carried out overnight at 4°C with rotation 
by using 4 µg of polyclonal anti-SP1 (Millipore, Billercia, MA) antibody. Protein A 
Agarose/Salmon sperm DNA were added to the chromatin-antibody complexes for 1h at 4°C 
with rotation. Washing and reverse crosslinking procedures were done according to the 
manufacturer’s guide (Millipore, Billercia, MA). PCR purification kit (Qiagen, Valencia, CA) was 
used for DNA elution from protein-DNA complexes. Immunoprecipitated DNA was analyzed for 
MET gene promoter sequence by PCR with proximal (5’-CAG GGC GAG AAA ACT TCT CCA 
CCT A-3’ and 5’-GCA CCG CCA GGC GAC CAG ACT GA-3’) and distal (5’-TCA GTC TTG 
GAG ATG TTG TTC CCA A-3’ and 5’-CCA GCA TGC AGA AGT TGG TGC TGA-3’) primer sets. 
Corresponding proximal region of mouse Met promoter sequence was analyzed by PCR with 
proximal primers (5’-GCT TTG CGC GGG TGA CTT TG-3’ and 5’-AGC ACG TGT CTG TTC 
GTC CCT G-3’) as previously described (Morozov et al., 2007). Advantage GC genomic LA 
polymerase mix (Clontech, Mountain View, CA) was used for PCR amplification of MET 
promoter region due to high GC contents. PCR products were separated on a 2% agarose gel 
and stained with ethidium bromide and were observed under UV light. The proximal region of 
82 
 
survivin promoter was used as positive control for SP1 binding (Esteve et al., 2007). Three 
independent ChIP assays were performed. The band intensity of PCR results were measured 
by ImageJ software, and normalized by 2% input control. 
 
Statistics. Statistical analyses were performed with InStat 3.10 and Prism 5.01 software 
(GraphPad, Inc., San Diego, CA). 
 
3.4 Results 
 
3.4.1 p53 inactivation leads to MET overexpression.  
 
To evaluate immediate transcriptome changes associated with p53 inactivation, we conducted 
mRNA microarray analysis of primary OSE cells after acute inactivation of p53, Rb or both p53 
and Rb concomitantly (Figure 3.1A and Figure 3.2). Interestingly, in addition to the expected 
targets of p53 and Rb/E2f signaling, upregulation of Met proto-oncogene was detected as a 
consequence of p53 and p53/Rb inactivation, but not of inactivation of Rb alone (Figure 3.2). 
According to qRT-PCR (Figure 3.1B) and Western blot analysis (Figure 3.1C), MET expression 
levels continued to rise for 72 hours after gene inactivation and were particularly high in 
neoplastic OSE cell lines (over 40 passages) deficient for p53 (OSN2) or p53 and Rb (OSN1). 
Consistently, p53 knockdown in human ovarian cancer cells OVCA433 and colon cancer cells 
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Figure 3.1 Inactivation of p53 leads to increase of MET expression. (A) Outline of 
experiments. After Ad-Cre-mediated p53 inactivation, the mRNA expression profile was 
generated followed by qRT-PCR and Western blot validation of identified targets and elucidation 
of their functions by experimental testing. (B-C) Levels of MET mRNA and protein in primary 
OSE cells before and after p53 inactivation or p53 and Rb inactivation according to qRT-PCR 
and Western blot analysis, respectively. Neoplastic OSE cell lines (over 40 passages) deficient 
for p53 (OSN2), or p53 and Rb (OSN1), have particularly high levels of MET. qRT-PCR data: 
n=4, mean ± S.D. (D) Representative examples (upper and lower rows) of MET expression in 
the OSE of p53fl/flRbfl/f Z/EG mice 72 hrs after exposure to either Ad-Cre (upper) or Ad-Blank 
(lower) delivered by trans-oviductal intrabursal injection. Z/EG reporter indicates Cre-loxP 
mediated recombination by expression of EGFP. Note co-localization (arrows, yellow) of MET 
(red) and EGFP (green) in OSE cells that underwent Cre-mediated recombination. Arrows 
indicate OSE. Double immunofluorescence. DAPI counterstaining. Scale bar, 100 µm. Kindly 
provided by Dr. Andres Matoso. 
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Figure 3.2 Gene expression profiles of p53 inactivated OSE cells. Gene expression profiles 
of OSE cells from p53fl/fl, Rbfl/fl and p53fl/flRbfl/fl mouse were analyzed after either Ad-LacZ or Ad-
Cre infection. Independent replicates were subjected to the analysis. Two class analysis (FDR < 
1%) between p53 inactivated (p53fl/fl and p53fl/flRbfl/fl with Ad-Cre) and control groups (Rbfl/fl with 
Ad-Cre and p53fl/flRbfl/fl with Ad-LacZ) was performed. A total of 76 and 52 genes were identified 
to be significantly downregulated (upper) and upregulated (lower), respectively, in the p53 
inactivated group. Among those genes, several were well established downstream targets of 
p53-mediated activation, such as p21, Mdm2, and Bax, and repression, such as cyclin B1. 
Kindly provided by Dr. Wei Wang, Cornell Microarray Core Facility.  
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HCT116 carrying wild-type p53 resulted in increased MET expression (Figure 3.3A). To 
examine whether MET overexpression would be detected in vivo early after p53 inactivation, 
Ad-Cre was delivered to the OSE of p53fl/flRbfl/fl Z/EG mice by transoviductal injection. 
Consistent with the cell culture experiments, elevated levels of MET were detected in OSE cells 
that had Cre-loxP mediated recombination according to expression of EGFP reporter 72 hours 
after Ad-Cre administration, but Ad-blank administration did not result in detectable MET or 
EGFP expression (Figure 3.1D). No morphologically detectable differences were observed 
between mutant and wild-type OSE at that time (Figure 3.3B). 
 
3.4.2 MET is essential for p53-controlled cell motility and invasion.  
 
Because increased motility and invasion are among the principal effects of upregulated MET 
signaling, those features were tested in p53-deficient OSE cells. Compared to cells with wild-
type p53, p53 null cells showed significantly increased cell motility in wound healing/time-lapse 
microscopy and migration assays as well as increased propensity for invasion in Matrigel 
chambers (Figure 3.4A-D, Figure 3.5A). Moreover, treatment of cells with MET ligand HGF 
enhanced migration and invasion even further (Figure 3.4A-B). The increased motility and 
invasion was accompanied by elevation of levels of phosphorylated MET (Figure 3.5B). To test 
the extent of MET contributions to these properties of p53 null cells, both genes were 
inactivated in OSE cells derived from p53fl/flMetfl/fl mice. Met inactivation abrogated the motility 
and invasion, but not proliferation phenotype associated with p53 inactivation (Figure 3.4E and 
Figure 3.6). Thus, MET signaling is essential for p53-controlled motility and invasion. 
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Figure 3.4 MET is essential for p53 inactivation-mediated cell motility and invasion. (A 
and B) Cell migration and invasion 24 hours after p53 inactivation either in absence or presence 
of 20 ng/ml HGF in the lower chamber. (C) Motility of primary p53fl/fl OSE cells 72 hrs after 
infection with either Ad-LacZ or Ad-Cre. Percentages (Mean ± SD) of closed wound area 0, 12 
and 24 hrs after the scratch were measured by TScratch software. (D) Tracking of individual 
wild-type (WT) and null p53 (Mut) cells (n=14 each) in wound healing assay using time-lapse 
microscopy followed by analysis with ImageJ multi-track software. (E) Invasion properties of 
primary OSE cells isolated from p53fl/fl and p53fl/flMetfl/fl mice. Cells (2.5 x 104) were seeded into 
either control or Matrigel inserts 24 hrs after Ad-LacZ or Ad-Cre infection with HGF (20 ng/ml) in 
the lower chamber. Invading cells were counted after staining under the microscope 20 hrs 
afterwards. Bars, SD (n=3). *p<0.05; **p<0.01; ***p<0.001.  
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Figure 3.6 Migration and invasion but not proliferation depends on MET presence after 
p53 inactivation. (A) Percentage of invasion was measured in OSE cells by using either Ad-
EGFP or Ad-Cre:EGFP. (B) Cre-loxP mediated recombination was confirmed by PCR. Floxed 
and recombined p53 allele were detected as 316 bp and 198 bp DNA fragments respectively. 
Wild-type, floxed and recombined Met allele were detected as 480 bp, 320 bp and 600 bp 
fragments, respectively. (C) Adenoviral infection efficiency was monitored by fluorescent 
microscopy one day after infection. Over 90% of cells showed strong green fluorescence. Scale 
bar, 500 µm. (D-E) Either Ad-LacZ or Ad-Cre infected OSE cells from p53fl/fl and p53fl/flMetfl/fl 
mice were seeded onto either empty or Matrigel insert for counting migrating (D) or invading (E) 
cells, respectively, in the presence of HGF (20 ng/ml). (F) OSE cells from either p53fl/fl or 
p53fl/flMetfl/fl mice were incubated with BrdU for 2 hrs 48 hrs after infection with Ad-Cre. BrdU 
positive cells were detected by anti-BrdU antibody and counted. Bar, SD, (n=3) ; N.S., not 
significant ; **p<0.01.  
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3.4.3 p53 has a miR-34-independent mechanism of MET regulation.  
 
Consistent with regulation of MET expression by p53, expression of p53 at levels comparable to 
those of endogenous activation resulted in decreased amounts of MET protein in both mouse 
and human neoplastic ovarian cell lines, OSN2 and SKOV-3, respectively (Figure 3.7A and 
Figure 3.8). 
 To test the extent of MET expression dependence on miR-34, ovarian neoplastic cells 
were subjected to increasing amounts of miR-34 precursor molecules in transient transfection 
experiments. Maximum reduction of MET expression was observed at 30 nM concentration with 
no apparent effect of further increases in amounts of miR-34a precursor molecule (Figure 3.9A-
B) or combination of miR-34a, b and c (Corney et al., 2010). No effect on MET promoter activity 
was observed after transfection of the full length MET promoter reporter construct (pGL2-
3.1MET) together with individual miR-34 family precursor molecules (Figure 3.9C). These 
observations were in agreement with bioinformatics predictions and experimental evidences that 
miR-34 regulates MET expression principally by targeting MET 3’-UTR (reviewed in (Hermeking, 
2007)). However co-transfection of miR-34a precursor together with wild-type p53, resulted in 
further downregulation of MET (Figure 3.7A), suggesting that p53 may have a miR-34-
independent mechanism of MET regulation. Similar effects of p53 and/or miR-34a precursor 
transfection on MET downregulation were observed in p53 null lung cancer cells NCI-H1299, 
indicating potential significance of these observations for pathogenesis of other types of 
epithelial cancers (Figure 3.9D). 
 To directly show the presence of miR-34-independent mechanism of MET regulation by 
p53, we isolated OSE cells from mir-34a-/-mir-34b/c-/- (triple knockout, TKO) mice, lacking the 
entire mir-34 family of genes. As expected, OSE cells from TKO mice showed higher level of  
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Figure 3.9 miR-34 and p53 effects on MET expression and promoter activity. (A-B) miR-
34a precursor molecules were transfected into SKOV-3 cells at 10 nM, 30 nM or 90 nM 
concentration. Note, that miR-34a transfection at 30 nM is sufficient for the maximum effect on 
MET downregulation. MET protein and mRNA level were measured by Western blot (A) and 
qRT-PCR (B) analysis. Bars, SD. n=3. **P<0.01. (C) The effect of miR-34 family on MET 
promoter activity. Individual miR-34 family members and pGL2-3.1MET promoter construct were 
co-transfected into SKOV-3 cells. Luciferase activity was measured 24 hrs after transfection. 
Bars, SD. n=3. (D) MET expression after transient transfection of p53 expression vector (pORF-
hp53) and/or miR-34a precursor molecule (30 nM) into NCI-H1299 cells. 
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MET compared with wild-type OSE cells (Figure 3.7B). Reconstitution of miR-34 by transfecting 
miR-34a precursor molecule resulted in downregulation of MET (Figure 3.7C). Notably, p53 
knockdown in TKO OSE cells led to an increase of MET expression (Figure 3.7D), confirming 
that p53 down-regulates MET expression in a miR-34-independent manner, in addition to miR-
34-dependent mechanism (Figure 3.7E). 
 
3.4.4 p53 suppresses MET promoter activity.  
 
To test if MET promoter activity can be affected by p53 through binding of p53 consensus 
sequence in ovarian cells, reporter constructs containing -2619 to +353 fragment of MET 
upstream sequence (3.1MET) and its shorter fragments (Gambarotta et al., 1996) were co-
transfected with p53 expression vector into SKOV-3 (Figure 3.10) and OSN2 cells (Figure 
3.11A-B). Transfection of p53 significantly suppressed the promoter activity of 3.1MET construct, 
as well as that of smaller fragments. Even when the putative p53 responsive element was 
mutated (0.65METm), p53 was still capable of repressing MET promoter activity comparably to 
the repression by corresponding wild-type promoter construct (0.65MET), indicating that the 
discrepancy between previous report (Seol et al., 1999) and our findings may be a result of cell 
type-specific effects. 
 To rule out the possibility that the observed effects of p53 on MET promoter activity were 
caused by global transcriptional repression by ectopically expressed p53, PG-13-luc and MG-
15-luc reporter constructs, containing 13 copies of wild-type p53 consensus sequence, and 15 
copies of slightly mutated p53 consensus sequence (El-Deiry et al., 1993), respectively, were 
co-transfected with plasmids expressing either wild-type or DNA binding domain mutant p53. 
Only wild-type p53 could activate PG-13-luc promoter activity in SKOV3 (Figure 3.11C) and  
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Figure 3.10 p53 suppresses MET promoter activity. (A) Promoter constructs used in this 
study. 3.1 Kb human MET promoter sequence including 5’-UTR region (3.1MET) and its shorter 
fragments were cloned into pGL2-luciferase vector. p53 putative response element (star) was 
mutated in 0.65METm. (B-C) MET promoter activity after co-transfection of p53 expression 
vector (pORF-hp53) with individual promoter constructs into SKOV-3 cells. Cell lysates were 
harvested for estimation of luciferase activity 48 hrs after transfection. Note that p53 response 
element mutation does not abolish MET promoter suppression by p53 (C). All experiments were 
performed in triplicates. Bars, SD. 
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Figure 3.11 MET promoter activity in OSN2 cells and involvement of SP1 in MET promoter 
activity. (A) p53 expression vector (pORF-hp53) and each promoter construct were co-
transfected in OSN2 cells. Cell lysates were harvested and luciferase activity was measured 24 
hr after transfection. (B) p53 responsive element  mutation does not abolish MET promoter 
suppression by p53. (C-D) PG13-luc, which contains 13 copies of p53 responsive elements, 
was co-transfected with pCMV, pCMV-wild-type p53 or pCMV-mutant p53 (V143A, R175H, 
R249S, and R273H) into SKOV-3 (C) and OSN2 (D) cell lines. MG15-luc, which contains 15 
copies of mutated p53 responsive elements, was co-transfected with pCMV, pCMV-wild-type 
p53 or pCMV-mutant p53 (V143A, R175H, R249S and R273H) in SKOV-3 (C) and OSN2 (D) 
cell line. (E) In web-based TF binding sites algorithm with 85 threshold score (default setting), 5 
potential SP1 binding sites were identified in both pGL2-0.37MET and pGL2-0.27MET. (F) 
OSN2 cells were pretreated with different doses of mithramycin A one hr before transfection 
with 0.27MET promoter construct. Every experiment was repeated 3 times. Bars, SD.  
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OSN2 cells (Figure 3.11D); all four mutant p53 constructs were unable to activate both promoter 
constructs.  
Furthermore, p53 has been shown to inhibit hypoxia-inducible factor-stimulated 
transcription by destabilizing hypoxia-inducible factor 1 alpha (HIF1A), one of the prominent 
regulators of MET promoter activity (Pennacchietti et al., 2003). However, p53 inactivation did 
not lead to accumulation of HIF1A in OSE cells (Figure 3.12A), likely because of uneven 
sensitivity of different cell types to hypoxia (Chi et al., 2006). Consistent with cell type-specificity, 
OSE cells and ovarian cancer cell lines (OVCA432, OVCA433 and OVCAR-3) did not 
overexpress MET under hypoxic conditions regardless of HIF1A accumulation (Figure 3.12B), 
unlike colon cancer HCT-116 cells (Figure 3.12C-D).  
 Another potential mechanism for p53-dependent regulation of MET is through CD44. 
CD44 is known to form a multimeric complex and cooperate with MET (Orian-Rousseau et al., 
2002). It has been also recently identified as a p53 (Godar et al., 2008) and miR-34 (Liu et al., 
2011) target. However, CD44 was not among genes significantly upregulated after p53 
inactivation in gene expression microarrays (Figure 3.2). Furthermore, ectopic p53 or miR-34 
expression did not affect CD44 levels in ovarian carcinoma cells (Figure 3.12E). 
 Taken together, these results show that MET suppression by p53 is unlikely to be the 
result of global transcriptional repression, HIF1A, or CD44 expression.  
  
3.4.5 p53 inhibits SP1 binding to MET promoter.  
 
Because p53 was able to suppress activity of non-overlapping promoter constructs 0.27MET 
and 0.37MET, transcription factor binding sites common for both constructs were searched for 
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Figure 3.12 Hypoxia does not affect HIF1A and MET expression, and CD44 is not affected 
by p53 expression in OSE cells. (A) p53fl/fl OSE cells were exposed for 24 hr to either 
normoxic (20% O2) or hypoxic (2% O2) conditions 24 hrs after exposure to Ad-LacZ or Ad-Cre. 
MET and HIF1A were detected by western blotting. (B) Three human ovarian cancer cell lines 
were exposed for 24 hrs to either normoxic (N ; 20% O2) or hypoxic (H ; 2% O2) conditions. (C-
D). HIF1A and MET expression in HCT-116 cell line exposed to either normoxic or hypoxic 
conditions. Western blotting (C) and quantitative RT-PCR (D). n=3 ; Bars, SD. (E) CD44 protein 
levels after pORF-p53 and miR-34a precursor molecule transfection into SKOV-3 cells.  
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by bioinformatics analysis. This search identified binding sites for the SP1 transcription factor 
(Figure 3.11E). To test whether SP1 is required for MET promoter activity, SKOV-3 and OSN2 
cells were treated with mithramycin A (mitA) to inhibit DNA binding of SP1 (Blume et al., 1991). 
MitA treatment suppressed luciferase expression under control of MET promoter in a dose-
dependent manner, indicating that SP1 is required for MET promoter activity (Figure 3.13A and 
3.11F). This suppression was not increased by p53 expression, indicating that p53 and SP1 
share a common molecular pathway to regulate MET promoter activity (Figure 3.13B).
 Coimmunoprecipitation experiments demonstrated that either ectopic or endogenous 
p53 physically interacts with endogenous SP1 in SKOV-3 and OVCA433 cells, respectively 
(Figure 3.13C-E). To test if p53 may inhibit SP1 DNA binding ability, ChIP experiments were 
performed with SP1 antibody and amplicons covering the distal and proximal region of the MET 
promoter, which contain and lack SP1 sites, respectively (Figure 3.13F). SP1 binding was 
selectively enriched on the proximal region of MET promoter. p53 expression resulted in 
significant reduction of SP1 binding (Figure 3.13G-H). Conversely, as expected, p53 did not 
affect SP1 binding to the survivin promoter (Figure 3.13G), which is repressed by p53 through 
recruitment of chromatin remodeling complexes (Esteve et al., 2007). Consistently, in mouse 
OSE cells, p53 inactivation led to an increase of SP1 binding to the corresponding mouse Met 
promoter proximal region (Figure 3.13I). Taken together, these results show that p53 is likely to 
suppress MET promoter activity through inhibition of SP1 DNA binding.  
 
3.4.6 Mutant p53 proteins interact with SP1 and their effects on OSE motility and invasion 
depend on MET.  
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Figure 3.13 p53 inhibits SP1 binding to MET promoter. (A) Effect of mithramycin A (mitA) on 
MET promoter activity. SKOV-3 cells were pretreated with mitA one hr before transfection with 
0.27MET promoter construct. (B) Individual and combined effects of mitA (100 nM) and p53 
expression on 0.27MET promoter activity in SKOV-3 cells. Bars, SD (n=3). *** p<0.001 (C-E) 
Detection of p53 and SP1 binding by co-immunoprecipitation. Either control (pORF, mock) or 
p53 expression vector (pORF-hp53, p53) was transfected into SKOV-3 cells. 48 hrs after 
transfection, cell lysates were immunoprecipitated with SP1 (C) or p53 (D) antibodies followed 
by Western blotting with p53 or SP1 antibodies, respectively. (E) OVCA433 cell lysates were 
either immunoprecipitated with SP1 antibodies, followed by Western blotting with p53 antibody 
(upper, IP:SP1). Samples of the same lysates were used for Western blotting with SP1 or p53 
antibody before precipitation (lower, WB). (F) Design of ChIP assays. The proximal region of 
MET promoter contains three potential SP1 binding sites (grey oval shapes), but the distal 
region has none. Arrows, primers for PCR amplified regions. (G-H). Qualitative (G) and 
quantitative (H) analyses of ChIP assays with SP1 antibody and the distal and proximal region 
of MET promoter. ChIP assay was performed 48 hrs after transfection of p53 vector into SKOV-
3 cells. 2% input control was loaded for comparison. The results are representative of three 
independent experiments. *P = 0.0182. Bars, SD. (I) Analysis of mouse Met promoter region 
corresponding to the proximal region of human MET promoter. ChIP assay was performed 48 
hrs after either Ad-LacZ or Ad-Cre infection of OSE cells from p53fl/fl mice.  
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To explore the role of mutant p53 in Met regulation, four expression vectors encoding DNA 
binding domain p53 mutants (V143A, R175H, R249S and R273H) were transfected with MET 
promoter reporter constructs into SKOV-3 and OSN2 cells. All mutant p53 vectors suppressed 
0.65MET and 0.27MET constructs, albeit less efficiently compared with wild-type p53 (Figure 
3.14A-B and Figure 3.15A-B). Accordingly, the mutant p53 proteins were co-immunoprecipitated 
with SP1 (Figure 3.14C), indicating that at least these common p53 mutants retain interactions 
with SP1. 
Cells of human ovarian cancer cell lines OVCA432 and OVCAR-3 carrying mutant p53 
did not show an increase of already high MET levels after p53 knockdown (Figure 3.15C). To 
further explore the role of mutant p53 in motility and invasion, primary OSE cells were prepared 
from p53+/LSLR172H and p53+/LSLR270H mice, which contain a conditionally activated copy of mutant 
p53 corresponding to human p53 R175H and R273H hot-spot mutations, respectively. Despite 
overall increased p53 expression after Ad-Cre infection (Figure 3.16A), Met expression 
increased only slightly (Figure 3.14D). While loss of both p53 copies is sufficient to immortalize 
OSE cells (18), p53+/R172H and p53+/R270H OSE cells had a very limited proliferation potential and 
underwent senescence (Figure 3.16B), consistent with previously reported phenotype of mouse 
embryonic fibroblasts (MEFs) carrying the same p53 mutations (Olive et al., 2004). 
 Similarly to MEF immortalization after the loss of remaining wild-type copy of p53, OSE 
cells from p53fl/LSLR172H and p53fl/LSLR270H mice were easily immortalized after Ad-Cre infection. In 
these cells levels of Met expression were higher than those in cells heterozygous for mutant p53 
but less than those in p53 null background (Figure 3.14E). Cells carrying mutant R172H or 
R270H p53 also displayed increased cell invasion, although at a lesser extent than that of p53 
null cells (Figure 3.14F). Similarly to observations in p53 null cells, deletion of Met abrogated 
increased migration and invasion associated with mutant R172H or R270H p53 (Figure 3.14G 
and Figure 3.16C).  
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Figure 3.14 Contribution of mutant p53 protein to OSE motility and invasion depends on 
MET. (A-B) Effects of wild-type and mutant p53 (V143A, R175H, R249S and R273H) on the 
activity of 0.65MET (A) and 0.27MET (B) promoter fragments in SKOV-3 cells. (C) Detection of 
SP1 binding to wild-type and mutant p53 after transient transfection into SKOV-3 cells. (D-E) 
Met expression in OSE cells from p53+/LSLR172H, p53+/LSLR270H, p53fl/LSLR172H and p53fl/LSLR270H mice 
48 hrs after Ad-Cre infection. qRT-PCR. n=3, mean ± SD. (F) Invasion of OSE cells from p53fl/fl, 
p53fl/LSLR172H and p53fl/LSLR270H mice 24 hrs after Ad-Cre infection. (G) Met inactivation abrogates 
increased invasion of OSE cells containing p53 R172H mutation. Bars, SD (n=3). *p<0.05; 
**p<0.01; ***p<0.001. 
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Figure 3.16 The role of mutant p53 in OSE cells. (A) OSE cells from p53+/LSLR172H or 
p53+/LSLR270H mice were infected by either Ad-LacZ or Ad-Cre. Slight increase of p53 was 
detected, likely because of mutant p53 expression in Western blot analysis. (B) OSE cells 
expressing mutant p53 were not immortalized and underwent senescence. Staining for 
senescence-associated β-galactosidase. Scale Bar, 500 µm. (C) Either Ad-LacZ or Ad-Cre 
infected OSE cells from p53fl/LSLR270H and p53fl/LSLR270HMetfl/fl mice were seeded on a control 
insert or Matrigel insert with serum free media and exposed to complete growth media 
containing 20 ng/ml HGF in the lower chamber. Migrating and invading cells were counted 20 
hrs after staining under the microscope. Bar, SD, n=3. **p<0.01. N.S. indicates ‘not significant’. 
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3.5 Discussion 
 
Our work shows that p53 controls the expression of the proto-oncogene MET by two 
mechanisms consisting of suppression of MET on the transcriptional level via promoter 
repression and on the post-transcriptional level via transactivation of miR-34. Contrary to a 
previous report (Seol et al., 1999), we were unable to find any canonical or novel p53 binding 
sites selectively responsible for either activation or repression of MET promoter. At the same 
time, the results of our promoter analysis, together with co-immunoprecipitation and ChIP 
assays, provide support for a mechanism of MET transcriptional repression based on inhibition 
of SP1 binding to DNA through physical interactions between p53 and SP1 rather than on direct 
promoter binding by p53. Consistent with this possibility, it has been previously reported that 
SP1 activates MET promoter activity (Verras et al., 2007; Zhang et al., 2003) and interacts with 
wild-type (Koutsodontis et al., 2001; Wierstra, 2008) and mutant p53 (Brosh and Rotter, 2009). 
Furthermore, p53 inhibits SP1 DNA binding on HIV-LTR and MGMT promoter in vitro 
(Bargonetti et al., 1997; Bocangel et al., 2009). 
 Either lack of p53 or expression of its mutant forms abrogate miR-34 transactivation 
(Hermeking, 2007). Therefore, both types of mutations result in elevation of miR-34-dependent 
MET expression. However, our study shows that unlike null mutations, mutant p53 protein 
retains MET promoter suppressive function, albeit to a lesser degree than wild-type p53. 
Consistent with the lesser extent of MET expression, cells expressing mutant p53 display a 
lower MET-dependent motility and invasion as compared to null mutants. These findings 
suggest that specific alterations in individual components of p53/MET signaling network may 
modulate the course of pathological process. Consistent with this possibility, the poorest 
118 
 
prognosis of p53 null mutation has been reported in some types of neoplasms, including ovarian, 
lung and breast cancers (Hashimoto et al., 1999; Lai et al., 2004; Sood et al., 1999). 
 Recent studies indicate that lack of p53 versus expression of mutant p53 proteins may 
have a different impact on motility and invasion in the context of particular cell lineages as well 
as additional genomic alterations. Our observations of increased motility and invasion by p53 
null OSE cells are consistent with previous studies that have shown comparable effects in p53 
null immortalized fibroblasts and MEFs (Alexandrova et al., 2000; Gadea et al., 2007). Similarly, 
non-small cell lung carcinoma line NCI-H1299 cells harboring a p53 null mutation have been 
reported to migrate faster than those expressing R175H mutant p53 (Kalo et al., 2007).  
 At the same time, some investigators have reported that mutant p53 protein but not null 
p53 mutations may drive cell motility and invasion by promoting integrin recycling (Muller et al., 
2009), by forming a complex with Smad to oppose p63-mediated control of putative metastasis 
suppressors Sharp-1 and cyclin G2 (Adorno et al., 2009) or by stabilizing the invasion promoter 
Slug (Wang et al., 2009). Consistent with cell-type specificity of p53 effects, mice expressing 
mutant p53 develop a more diverse spectrum of neoplasms as compared to null mutants (Olive 
et al., 2004). Interestingly, in line with observations by Grugan et al. (Grugan et al., 2010), 
knockdown of mutant p53 in ovarian carcinoma cells did not change levels of MET expression. 
This observation is at variance with our results on primary OSE cells carrying conditional mutant 
p53 allele, which may indicate that established cancer lines and neoplastic cells at advanced 
cancer stages develop additional mechanisms ensuring MET signaling in cells carrying mutant 
forms of p53 protein. Assessment of primary ovarian cancer cells should address this problem 
in future studies. It should be also of interest to evaluate p53/MET signaling in the fallopian tube 
epithelium, another potential cell of origin of serous adenocarcinoma of the ovary (Kindelberger 
et al., 2007; Piek et al., 2001). 
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 There are indications that some additional genetic or epigenetic alterations are required 
for stabilization and accumulation of mutant p53 thereby leading to gain-of-function phenotype 
(Terzian et al., 2008). In agreement with this possibility, our results in primary OSE from 
p53+/R172H or p53+/R270H mice, as well as studies by others in MEFs with the same genotypes 
(Olive et al., 2004), show that cell immortalization is acquired only after the loss of the remaining 
wild-type copy of p53. Consistently, Adorno et al. (Adorno et al., 2009) were able to observe 
increased migration of cells expressing mutant p53 only in combination with HRAS and TGFβ 
signaling. Notably RAS mutations are extremely rare in high grade serous ovarian carcinoma 
(Bast et al., 2009).  
 Development of therapies aimed at correction of the p53 pathway remains among the 
most coveted goals in cancer research (Brown et al., 2009). Importantly, our experiments have 
demonstrated that MET is a critical component of motility and invasion in cells either lacking p53 
or expressing its mutant forms. Therefore, treatment of cancers with p53 mutations is likely to 
benefit from therapeutics aimed at MET, such as small targeting molecules (Comoglio et al., 
2008). This finding is of particular significance because, despite successful outcomes in cell 
culture and animal in vivo experiments, direct re-introduction of the p53 gene failed in clinical 
trials, including EOC (Zeimet and Marth, 2003). Our study also indicates that approaches aimed 
at indirect elimination of mutant p53 protein (e.g., by p53 siRNA) should be avoided in cancers 
with active p53/MET signaling network. The in-depth understanding of mechanisms by which 
p53 regulates MET in the context of different cell types, as well as specific p53 mutations, may 
be essential for future development of individualized therapeutics. 
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CHAPTER 4 
 
GENERATION AND CHARACTERIZATION OF MICE WITH CONVENTIONAL AND 
CONDITIONAL INACTIVATION OF MIR-34 FAMILY  
 
4.1 Abstract 
 
Genes encoding for miR-34 family have been shown to be a direct target of transcriptional 
activation by p53 tumor suppressor. Since miR-34 is highly evolutionarily conserved and targets 
multiple proteins involved in cell cycle (Cdk4, Cdk6, Cyclin D1, E2F3), stem cell maintenance 
(Notch1 and 2, EZH2), metabolism (SIRT1), cell motility (Met), apoptosis (Bcl-2) and induced 
pluripotent stem (iPS) cell reprograming (c-Myc and Klf4), it has been expected to play a variety 
of essential regulatory roles in a number of important biological processes. Furthermore, since 
miR-34 is deleted or downregulated in many cancers, it has been proposed to have a tumor 
suppressor function. However, direct genetic testing of specific roles of miR-34 family during 
development and carcinogenesis has not been performed so far. Furthermore, it remains 
unclear to which extent miR-34 contributes to p53 effects, such as DNA damage response and 
iPS cell reprogramming. To address these issues we have prepared mice carrying conventional 
and conditional alleles of mir-34a and mir-34b/c. We report that similarly to p53 deficient 
phenotype, mice lacking all mir-34genes are viable. However, at variance to p53 mice, mir-34a-/- 
mir-34b/c-/- mice do not develop lymphomas within first 3 months of age but exhibit thymic and 
splenic hypoplasia, ulceration of forestomach and focal hyperplasia of Purkinje neurons. 
Furthermore, in spite of accelerated proliferation, which is similar to that of p53 deficient cells, 
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mir-34 deficient cells do not show increased reprogramming efficiency, indicating that this 
parameter is  insufficient for facilitation of reprogramming by p53. mir-34b/c deficiency also 
caused radioresistance to 15 Gy ionizing radiation (gastrointestinal tract syndrome) but not 10 
Gy (hematopoietic syndrome), contrary to known radiosensitivity and radioresistance, 
respectively, of  p53 deficient mice. Taken together, these findings indicate that in spite of direct 
regulation by p53, miR-34 has a significant set of distinct biological functions. Availability of mice 
with conventional and conditional inactivation of all miR-34 family members will provide the 
necessary basis for further detailed characterization of mir-34 biological functions and 
determining their place within p53 signaling network during development and carcinogenesis.  
 
4.2 Introduction 
 
microRNAs (miRNAs) are a class of small non-coding RNAs that function to control gene 
expression. Recent studies have shown the tumor suppressive and oncogenic potential of a 
number of miRNAs, underscoring their importance in human cancer therapeutic and diagnostic 
applications (Reviewed in (Corney and Nikitin, 2008; Farazi et al., 2011; Reddy et al., 2010)). 
One of the most intensively studied miRNAs is miR-34 family, which is among the most 
evolutionary conserved miRNAs (Grad et al., 2003). miR-34 family is encoded by the mir-34a 
gene located on human chromosome 1 and miR-34b and mir-34c genes located on human 
chromosome 11 (chromosomes 4 and 9, respectively, in mouse). miR-34a is transcribed alone, 
while miR-34b and miR-34c share a common primary transcript as a cluster (Corney and Nikitin, 
2008). The first evidence for potential involvement of miR-34 family in cancer has arisen from 
reports of a minimal deleted region 11q23-q24-D containing mir-34b/c in lung and breast 
cancers (Calin et al., 2004), and 1p37 containing mir-34a, frequently deleted in high-risk 
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neuroblastoma (Cole et al., 2008; Welch et al., 2007). In 2007 several groups, including our 
laboratory, independently reported that miR-34 family is a direct target of p53 transactivation 
(Bommer et al., 2007; Chang et al., 2007; Corney et al., 2007; He et al., 2007; Tarasov et al., 
2007). Loss or decreased expression of miR-34 has been reported in multiple cancer cell lines 
and human malignancies (summarized in Table 1.2). The high frequency of miR-34 
downregulation in human cancer and its correlation with advanced stages of the diseases and 
poor prognosis suggests that genes of mir-34 family are putative tumor suppressors. In addition, 
the tumor suppressive role of miR-34a has been shown by in vivo delivery in lung and 
pancreatic cancer models (Pramanik et al., 2011; Trang et al., 2011). However, a direct genetic 
proof of mir-34 family's role as tumor susceptibility/suppressor genes has been missing. 
 Ectopic expression of miR-34 has been shown to regulate cell cycle, apoptosis, 
senescence, cell migration and invasion through regulating target genes (Reviewed in 
(Hermeking, 2010)). Validated targets for cell cycle regulation include CDK4, CDK6, Cyclin E2 
and Cyclin D1, associated with G1-arrest (Bommer et al., 2007; Fujita et al., 2008; He et al., 
2007; Sun et al., 2008). As an important target for apoptosis and DNA damage response, Bcl-2 
is a validated target of entire miR-34 family members (Ji et al., 2009). As described in Chapter 2 
and 3, anti-migratory and anti-invasive effect of miR-34 appears to be mainly through 
posttranslational regulation of MET proto-oncogene (Corney et al., 2010; He et al., 2007; 
Migliore et al., 2008). In addition, miR-34 family is also involved in a various cellular responses 
such as senescence (Sirt1) and stem cell maintenance (Notch1, 2 and Jagged-1) (Li et al., 
2009b; Pang et al., 2010; Yamakuchi et al., 2008). Particularly, the involvement of miR-34 family 
control of stemness genes suggests that miR-34 family may play a role in regulation of normal 
and neoplastic stem cells as well as iPS cell reprogramming process. 
An important finding to understand the mechanism of iPS cell reprogramming process 
was the involvement of p53 (Menendez et al., 2010). Consistently, miR-34a is also known to 
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target c-Myc (Cannell et al., 2010; Christoffersen et al., 2010), one of the initially identified 
reprogramming factors (Takahashi and Yamanaka, 2006). Interestingly, miR-34a inhibition in 
embryonic stem cells has been shown to delay cell differentiation in LIF free condition 
(Tarantino et al., 2010), suggesting the potential role of miR-34a in stem cell self-renewal and 
differentiation. Thus, it is reasonable to hypothesize that the p53-mediated barrier to 
reprogramming may be due to miR-34 family at least in part. However, it remains unknown if 
inactivation of mir-34 may promote the reprogramming of somatic cells into iPS cells.  
p53 activation followed by initiation of cell apoptosis or senescence in response to DNA 
damage is one of the key tumor suppression mechanisms, because DNA damage and genomic 
instability commonly accompany tumor progression (Meek, 2009). Since genotoxic insults 
induce expression of miR-34 family in p53-dependent manner it is possible that miR-34 is 
involved in mediating p53 downstream signaling leading to cell apoptosis or senescence in a 
cell type specific manner. Consistent with a cell type specificity of DNA damage response, in C. 
elegans mir-34 mutation caused radiosensitive phenotype in the soma and radioresistance in 
the germline (Kato et al., 2009). At the same time, ectopic expression of miR-34a resulted in 
radiosensitivity in colon cancer cell line (Liu et al., 2011) but radioresistance in breast cancer 
cell line (Kato et al., 2009). The precise role of miR-34 in DNA damage response in mammals in 
vivo remains to be determined.  
In order to study the precise role of miR-34 family in physiologically relevant settings, we 
decided to inactivate mir-34 genes in the mouse. Here we report the generation of mice with 
conventional and conditional deletion of mir-34a, as well as preparation and initial 
characterization of mice deficient for entire mir-34 family. We demonstrate that mice lacking all 
mir-34 genes are alive but show defects in several systems, such as hypoplasia of the thymus 
and the spleen, ulceration of the forestomach and focal hyperplasia of Purkinje neurons.  Loss 
of mir-34 resulted in increased cell proliferation but did not improve iPS cell reprogramming 
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efficiency. In addition, mir-34b/c deficiency caused radioresistant phenotype upon 15 Gy IR, 
suggesting that miR-34 is involved in DNA damage response. Taken together, these findings 
indicate that miR-34 family has a number of biological functions which do not recapitulate those 
of p53. 
 
4.3 Materials and methods 
 
BAC recombineering and construction of mir-34a targeting vector. The conditional gene-
targeting vector was constructed using a recombineering approach as described elsewhere (Liu 
et al., 2003). Detailed recombineering protocols, plasmids (PL253, PL451 and PL452) and 
E.coli strains (EL250 and EL350) can be found on website at http://recombineering.ncifcrf.gov. 
Mini-targeting vector 1 which contains two homology arms flanking 12 Kb genomic sequence of 
pre-mir-34a to be subcloned by gap repair was cloned into PL253 plasmid. The primers used for 
amplification of the 5' and 3' homology arms were as follows: 5' arm F, 5' AGTCG CGGCC 
GCGCT AAATG AGGAC TTCGT GACAA A 3'; 5' arm R, 5' CAATC AGTTC ACAAC CACTT 
GGTA 3'; 3' arm F, 5' AGGGA TCCCA CAGGC AAGGG TGTGG GTTCA 3'; and 3' arm R, 5' 
ATCTA GATTT CTCAA AATGT CACCA GTGTT CA 3'. Mini-targeting vector 2 which contains 
two homology arms for 5’ of pre-mir-34a was cloned into PL452 plasmid. The primers used for 
amplification of the 5’ and 3’ homology arms were as follows: 5’ arm F 5’ AGGGT ACCAG 
CCAGC AGGGA ATAGT GGTCA 3’; 5’ arm R, 5’ AGAAT TCCAC ATCAG GCAAA ACACG 
TATAC A3’; 3’ arm F, 5’ AGGGA TCCTA TACAC TGTGT GTGTG CCTGG TA 3’; and 3’ arm R, 
5’ AGTCG CGGCC GCCCC AGGCT GAGGC GCCCG CA 3’. Mini-targeting vector 3 which 
contains two homology arms for 3’ of pre-mir-34a was cloned into PL451 plasmid. The primers 
used for amplification of the 5’ and 3’ homology arms were as follows: 5’ arm F 5’ AGGGT 
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ACCAT CTTTA CCCAC TGAAC CATCC CGA 3’; 5’ arm R, 5’ AGAAT TCCTC GTGTG TGCGG 
CTTCG GGCA 3’; 3’ arm F, 5’ AGGGA TCCGC TTCAC ATTTT TTCAG TTTTC CTA 3’; and 3’ 
arm F, 5’ AGTCG CGGCC GCGCC TTGTA CTTGG AGAGA TCCA 3’. 
 
Embryonic stem (ES) cell culture. The E14 mouse embryonic stem cell line was cultured in 
undifferentiating conditions on mitotically inactivated feeder cells and in the presence of 
leukemia inhibitory factor (LIF) at 37°C in 10% CO2. Briefly, medium used was Dulbecco’s 
Modified Eagle Medium (high glucose) containing 15% heat-inactivated ES cell qualified fetal 
bovine serum, 6 mM L-glutamine, 1 mM sodium pyruvate, 1x Dulbecco’s non-essential amino 
acids (all purchased from Invitrogen, Carlsbad, CA) plus 10-4 M 2-mercaptoethanol (Sigma, St. 
Louis, MO), and 103 units/ml LIF (Millipore, Billerica, MA). For positive and negative selection, 
cells were cultured in the medium containing 200 μg/ml G418 and 0.2 µM Ganciclovir. 
 
Primary cell cluture. Mouse embryonic fibroblast (MEF) cells were prepared from 13.5-15.5-day 
old C57Bl/6 embryos carrying neomycin cassette under control of PGK promoter (C57BL/6J-
Tg(pPGKneobpA)3Ems/J, The Jackson Laboratory, Bar Harbor, ME; stock number 002356) and 
prior to use as feeder cells mitotically inactivated by exposure to 10 μg/ml mitomycin C for one 
hour at 37°C followed by three washes with phosphate-buffered saline (PBS). ES cells were 
routinely passaged using 0.25% trypsin/EDTA prior to reaching confluence. Feeder cells were 
separated from ES cells by differential attachment to gelatinized plates for one hour at 37°C. For 
tail-tip fibroblasts (TTFs) culture, 1 cm length of tail-tip was cut, minced and incubated with 
DMEM containing 10% FBS, 6 mM L-glutamine, 1 mM sodium pyruvate and 
penicillin/streptomycin. Lipofectamin 2000 reagent (Invitrogen, Carlsbad, CA) was used for the 
transfection following manufacturer’s recommendations. 
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Mice. mir-34b/c conditional and conventional knock-out mice were generated by Dr. David 
Corney in our laboratory (Corney, 2010). While mir-34a conditional and conventional knock-out 
mice were being generated in by us, mir-34a conditional knock-out mice were independently 
generated and provided to us by our collaborator Dr. Heiko Hermeking (Ludwig-Maximilians-
University Munich). Hermeking's mice were used for OSE experiments (described in Chapter 3), 
pathological evaluation and iPS cell reprogramming in this study. Transgenic mice with carrying 
Flp transgene (129S4/SvJaeSor-Gt(ROSA)26Sortm1(FLP1)Dym/J) and Cre transgene (FVB/N-
Tg(EIIa-cre)C5379Lmgd/J) were purchased from Jackson laboratory (Bar Harbor, Maine). 
Deletion of the Neo cassette was obtained by crossing to Flp transgenic mice. Both ours and 
Hermeking's mir-34aloxP/loxP mice were crossed with mir-34b/cloxP/loxP mice to obtain mice with 
knockout of all mir-34 genes. Additionally they were crossed with Cre transgenic mice (EIIa-Cre) 
to obtain mice with conventional mir-34 knockout. All of the mice were maintained identically, 
following recommendations of the Institutional Laboratory Animal Use and Care Committee. 
 
Body weight measurements. Body weights of mir-34a-/- mir-34b/c-/- female mice (n=5; 13, 24, 32, 
42 and 73 days old) and similar ages of mir-34aloxP/loxP mir-34b/c loxP/loxP female mice (n=7) were 
measured under identical conditions at the same time of the day. 
 
Pathological Analyses. Mice were subjected to careful evaluation during necropsy and the brain, 
lung, thymus, stomach, small intestine (the proximal and distal part), large intestine (colon), 
kidney, ovary, uterus, spleen, pancreas, mammary gland, heart and thigh muscle were collected 
for histological processing. Tissues were placed into PBS-buffered 4% paraformaldehyde, fixed 
overnight at 4ºC and embedded in paraffin. Prepared 4 μm paraffin sections were stained with 
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Hematoxylin and Eosin and subjected to pathological evaluation. Sections of the proximal 
region (6 cm distally to the stomach) and the distal region (2 cm proximal to the cecum) of the 
small intestine were prepared as described by (Kirsch et al., 2010). All tissues and organs were 
collected from mir-34a-/- mir-34b/c-/- female mice and age- and sex-matched wild-type female 
mice. Since age- and sex-matched wild-type littermates for mir-34a-/- mir-34b/c-/- mice from mir-
34a+/- mir-34b/c+/- crosses are expected to have low frequency, age- and sex-matched mir-
34aloxP/loxP or mir-34b/cloxP/loxP mice were also used as control.  
 
PCR for genotyping. 5’ arm of mir-34a containing a loxP site was amplified by using F 5’ 
GAATG TGTAT ACGTG TTTTG CCTGA 3’ and R 5’ TAAC TCCAG TTACA GGGAC TCTGA 3’. 
Wild-type allele generated 100 bp, and targeted allele 198 bp, shown in Figure 4.3.C. In order to 
amplify wild-type, floxed allele and null allele together, multiplex PCR was done by using three 
primers (1) F 5’ GAATG TGTAT ACGTG TTTTG CCTGA 3’, (2) F 5’ AGCTG ACATG CCAGG 
AATGC TGA  3’, and (3) R 5’ TGGCC CCTTT AATTT ACAAG CCCA 3’. Wild-type allele 
generates 196 bp, floxed 293 bp, and null 216 bp respectively, shown in Figure 4.4. 
 
Southern blotting. Genomic DNA was isolated from ES clones in DNA lysis buffer (100mM NaCl, 
50mM Tris-HCl pH 7.5, 10mM EDTA pH 8.0, 0.5% SDS and 100 µg/ml Proteinase K). Genomic 
DNA was digested by SphI, resolved in 0.8% Agarose gel, and transferred to Zeta probe 
membrane (BioRad, Hercules, CA). Genomic DNA sequence for probe region was PCR-
amplified by using primers F 5’ GTGAC ATTTT GAGAA ATTGA AACAA 3’ and R 5’ ACCTT 
ATAAA AGAAG ACAGC ACCA 3’. PCR product was cloned into T-vector, digested by 
restriction enzyme, and gel-purified. Southern blotting probe was prepared by 32P-dCTP end-
labeling. Purified probe was hybridized with membrane in Church buffer (7% SDS, 1% bovine 
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serum albumin, 1mM EDTA, Na2HPO4 0.25M, pH 7.2). After washing, membrane was exposed 
to phosphorscreen. 
 
Ionizing irradiation (IR). Mice were placed in irradiation chambers and whole-body radiation was 
performed with a sealed 137Cs source irradiator Mark 1-68 (JL Shepherd and Associates, San 
Fernando, CA) at a dose rate of approximately 120.3 cGy/min. Irradiated mice were monitored 
twice a day and euthanized as scheduled or at the time of becoming moribund.  
 
In situ hybridization. Detection of miR-34a was done by the protocol adapted from Nelson et al. 
(Nelson et al., 2006). To prevent the loss of miRNAs, we additionally applied 1-ethyl-3-(3-
dimethylaminopropyl) carbodiimide (EDC) fixation as described by Pena et al. (Pena et al., 
2009). In brief, 4-μm-thick sections of formalin fixed, paraffin-embedded material were 
deparaffinized, rehydrated, and fixed with EDC. After 1-h prehybridization, a digoxigenin (DIG)–
labeled locked nucleic acid (LNA) probe (Exiqon, Woburn, MA) was hybridized to proteinase K–
treated sections at 56°C for 16 h. Slides were then incubated with anti-DIG-AP antibody (Roche, 
Indianapolis, IN), and miRNA expression was detected by nitrobluetetrazolium/5-bromo-4-
chloro-3-indolyl phosphate method. Methyl green was used for nucleic counterstaining. 
 
iPS cell reprogramming. Reverse tetracycline transactivator (R26-M2rtTA) construct driven by 
the ROSA26 promoter and doxycycline-inducible Oct-4, Klf-4, Sox-2 and c-Myc lentiviral 
constructs were described by (Brambrink et al., 2008). In brief, 293T cells were transfected with 
a mixture of viral plasmid and packaging constructs expressing the viral packaging functions 
and the VSV-G protein. Medium was replaced 24 hours after transfection, and viral 
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supernatants were collected at 48 hours. TTFs or MEFs were incubated with viral supernatants 
and fresh media at a ratio of 1:1 for 24 hours according to commonly used methods at Cornell 
Induced Pluripotent Stem Cell Core. 6.4 x 104 TTFs and 7.2 x 104 MEFs were plated on 6 cm 
tissue culture dish and doxycycline (1.5 µg/ml final concentration) was daily added to the cell 
culture medium starting from 1 day following the split. Cell number for growth analysis was 
measured 1 and 2 days after doxycycline treatment.  
 
Alkaline phosphatase (AP) and Nanog staining. AP staining kit (Vector Laboratories, Burlingame, 
CA) was used according to manufacturer’s instructions. For Nanog staining, standard 
immunohistochemistry protocol was applied as described elsewhere (Nikitin and Lee, 1996). 
Briefly, rabbit polyclonal antibody against Nanog (1:50, #80892, 1 hour incubation at room 
temperature, Abcam, Cambridge, MA) was detected by goat anti-rabbit biotinylated secondary 
antibody and followed by ABC-Elite (Vector laboratories, Burlingame, CA). The efficiency of 
reprogramming was calculated as the relative change compared to that of control experiments. 
 
Statistics. Statistical and survival analyses were performed with InStat 3.10 and Prism 5.01 
software (GraphPad, Inc., San Diego, CA). 
 
4.4 Results 
 
4.4.1  Preparation of  mir-34aloxP/loxP targeting construct by BAC recombineering 
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In order to generate mir-34a targeting construct, BAC recombineering technology was used. 
RP23-410P10 BAC clone (C57Bl/6 genomic DNA; BACPAC Resource Center at Children's 
Hospital Oakland Resarch Institute, California) containing mir-34a locus was electroporated into 
EL350 E.coli cells. BAC integrity was confirmed by PCR and restriction enzyme digestion 
pattern analysis. The procedure of mir-34a targeting vector construction consists of 3 steps: (1) 
the retrieval of genomic DNA sequence containing mir-34a locus with Thymidine kinase 
cassette, (2) insertion of one loxP site in 5’ of mir-34a locus, and (3) insertion of FRT-flanked 
Neo cassette with one loxP site (Figure 4.1). In order to obtain 12 Kb genomic sequence 
containing mir-34a locus and insert Thymidine kinase cassette for negative selection as a first 
step, mini-targeting vector 1 which has a PL253 backbone and 500 bp 5’ and 3’ homologous 
arms was generated. Linearized mini-targeting vector 1 was electroporated into heat shocked 
EL350 E.coli containing a RP23-410P10 BAC sequence. Ampicillin-resistant clones were 
selected, and mir-34a-TK plasmid was obtained. In order to insert a loxP site in 5’ arm of mir-
34a locus, mini-targeting vector 2 which contains PL452 backbone and 500 bp 5’ and 3’ 
homologous arms was generated. Linearized mini-targeting vector 2 was PCR-amplified, 
digested by restriction enzyme, gel-purified and co-electroporated with linearized mir-34a-TK 
plasmid into heat shocked EL350 E.coli. Kanamycin-resistant clones were selected, and loxP-
Neo-loxP-mir-34a-TK plasmid was obtained. Electroporation of loxP-Neo-loxP-mir-34a-TK 
plasmid into heat shocked and arabinose treated EL350 E.coli cells resulted in Cre recombinase 
expression and Neo cassette removal. As a result, loxP-mir34a-TK plasmid was obtained. In 
order to insert a FRT-flanked Neo cassette with a loxP site in 3’ of mir-34a locus, mini-targeting 
vector 3 which has a PL451 backbone and 500 bp 5’ and 3’ homologous arms was generated. 
Linearized mini-targeting vector 3 was PCR-amplified, digested by restriction enzyme, gel-
purified and co-electroporated with linearized loxP-mir-34a-TK plasmid. Kanamycin-resistant 
clones were selected, and final mir-34a targeting construct was obtained. To validate loxP-Cre 
and FRT-Flpe recombination, mir-34a targeting construct was electroporated into heat-shocked  
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Figure 4.1 mir-34a targeting strategy. The mir-34a allele was conditionally targeted by 
homologous recombination to introduce loxP sites flanking the pre-mir-34a sequence. In the first 
step, around 12Kb of genomic DNA sequence containing pre-mir-34a was gap-retrieved into 
PL253 backbone plasmid by homologous recombination. In the second step, a neomycin 
cassette flanked by loxP sites (black triangle) was inserted, and removed by arabinose-inducible 
Cre recombinase expression, which allows one loxP site in 5' of pre-mir-34a. In the third step, a 
neomycin cassette flanked by FRT sites (green triangle) with a loxP site was inserted in 3' of 
pre-mir-34a. 
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and arabinose-treated EL350 and EL250 respectively, and correct recombination was confirmed 
by restriction enzyme digestion pattern analysis (Figure 4.2). 
 
4.4.2 Gene targeting and generation of mice containing conditional mir-34a allele 
 
Linearized mir-34a targeting vector was electroporated into E14 mouse ES cells (Figure 4.3A), 
and cultured on the top of feeder cells with G418 (200 µg/ml) and Ganciclovir (0.2 µM) for 
positive and negative selection respectively. ES clones (n=293) were picked up, and screened 
for correct homologous recombination by Southern blotting (Figure 4.3B). Clone #241 
underwent correct homologous recombination, and further confirmed by PCR analysis (Figure 
4.3C). Correctly targeted clone (#241) harboring both the single 5' loxP site and the 3' Frt-loxP-
flanked neo cassette were injected into C57BL/6 blastocysts, using standard procedures. After 
germ line transmission of the targeted allele, the null and conditional alleles were obtained by 
crossing to EIIa-Cre and Flp transgenic mice, respectively (Figure 4.4). 
 
4.4.3 Characterization of mir-34a-/- mir-34b/c-/- mice during development 
 
mir-34a-/- mir-34b/c-/- mice were obtained from crosses between mir-34a-/- and mir-34b/c-/-mice. 
mir-34a-/- mir-34b/c-/- mice were born alive and phenotypically indistinguishable from mir-
34aloxP/loxP mir-34b/cloxP/loxP mice. mir-34a-/- mir-34b/c-/- mice were born at the expected Mendelian 
ratio (Table 4.1, 4.2 and 4.3), and had similar body weights (Figure 4.5) and no gross 
abnormalities. To confirm loss of miR-34 expression, brain tissues and ovarian surface epitheli-  
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Figure 4.3 mir-34a targeting strategy and confirmation of correct homologous 
recombination. A. Schematic diagram of targeting of conditional mir-34a allele. Black and 
green arrowheads indicate loxP and FRT sites, and SphI enzyme recognition sites are indicated. 
Black arrows indicate genotyping PCR region. B. Southern blotting of 3’ arm (external probe). 
Genomic DNA from ES clones was isolated, digested with SphI, resolved with 0.8% agarose, 
transferred onto the membrane, and hybridized with radio-labeled probe. 9.4 Kb band indicates 
wild-type allele, and 5.2 Kb band a targeted allele. C. PCR genotyping confirms the presence of 
a loxP site in 5’ of pre-mir-34a. 100 bp band indicates wild-type allele, and 198 bp a targeted 
allele (lane 1: ES clone without correct homologous recombination, lane 2: ES clone #241 that 
underwent correct homologous recombination). 
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Table 4.1 Genotypes of mice resulting from crosses between mir-34a-/-mir-34b/c+/- and mir-34a-/-
mir-34b/c+/- mice 
 
Genotypes % Expected frequency % Frequency (n) 
mir-34a-/- mir-34b/c+/+ 25 % 25 %(n=8) 
mir-34a-/- mir-34b/c+/- 50 % 47 % (n=15) 
mir-34a-/- mir-34b/c-/- 25 % 28 % (n=9) 
Total 100% 100 % (n=32) 
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Table 4.2 Genotypes of mice resulting from crosses between mir-34a+/- mir-34b/c-/-and mir-34a-/- 
mir-34b/c+/- mice 
 
Genotypes % Expected frequency % Frequency 
mir-34a+/- mir-34b/c+/- 25 % 24 % (n=7) 
mir-34a-/- mir-34b/c+/- 25 % 24 % (n=7) 
mir-34a+/- mir-34b/c-/- 25 % 31 % (n=9) 
mir-34a-/- mir-34b/c-/- 25 % 21 % (n=6) 
Total 100 % 100 % (n=29) 
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Table 4.3 Genotypes of mice resulting from crosses between mir-34-/- mir-34b/c-/- with mir-34a-/- 
mir-34b/c+/- mice 
 
Genotypes % Expected frequency % Frequency 
mir-34a-/- mir-34b/c+/- 50 % 45 % (n=5) 
mir-34a-/- mir-34b/c-/- 50 % 55 % (n=6) 
Total 100 % 100 % (n=11) 
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um (OSE) were isolated from mir-34a-/- mir-34b/c-/- and wild-type mice, and miR-34 family 
expression level was confirmed (Figure 4.6). As expected, expression of MET, one of the 
shared targets of miR-34 family was increased in mir-34a-/- mir-34b/c-/-OSE compared to wild-
type OSE (described in Chapter 3, Figure 3.7B). 
Unlike p53-/- mice, mir-34a-/- mir-34b/c-/- did not develop hematopoietic malignancies, 
such as lymphoma by 6 months of age.  In order to explore any postnatal defects in mir-34a-/-
mir-34b/c-/- (triple knock-out, TKO) mice, one 3 weeks-old and two 9 weeks-old female TKO 
mice were sacrificed together with age- and sex-matched wild-type mice of similar genetic 
background.  
During necropsy, it was noted that TKO mice had significantly reduced sizes of spleens 
and thymuses by 9 weeks of age (Figures 4.7 A and B and 4.8 A and B). In 3 weeks old TKO 
mice, there was no histologically detectable difference in the spleen, as compared to age-
matched wild-type (Figure 4.7C and D). To the contrary, 9 weeks old TKO mice showed 
hypoplasia of white pulp and splenic atrophy compared to wild-type mice (Figure 4. 7A, B, E and 
F). Similarly, the thymuses from 3 weeks old wild-type and TKO mice had no histologically 
detectable differences (Figure 4. 8C and D). However, in 9 weeks old TKO mice, the overall size 
of thymus was smaller than that of wild-type (Figure 4. 8A and B), and the cortex region of the 
thymus was not distinguishable from the medulla region, while wild-type TKO mice had clear 
demarcation between the cortex and the medulla regions (Figure 4. 8E and F). This indicates 
that the thymus in TKO mice undergoes accelerated aplasia as compared to wild-type mice 
during postnatal development. The forestomach of both 9 weeks old TKO mice showed 
hyperplasia and ulceration of the squamous epithelium (Figure 4. 9A and B). In addition, focal 
hyperplasia of Purkinje neurons was detected in the cerebellum of one of two 9 weeks old TKO 
mice  (Figure 4. 9C and D). 
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4.4.4 iPS cell reprogramming 
 
Loss of p53 has been shown to facilitate iPS cell reprogramming efficiency (Hanna et al., 2009; 
Hong et al., 2009; Kawamura et al., 2009; Li et al., 2009a; Marion et al., 2009; Utikal et al., 
2009). Furthermore, c-Myc and Klf4 are among downstream targets of miR-34 (Christoffersen et 
al., 2010; Kong et al., 2008; Lujambio et al., 2008 and our unpublished observations). Thus, we 
hypothesized that mir-34 family inactivation may recapitulate loss of p53 in iPS cell 
reprogramming at least in part. First, we isolated TTFs from TKO and age-matched wild-type 
mice, and subjected to them to iPS cell reprogramming with 4 (Oct-4, Klf-4, Sox-2 and c-Myc) 
and 3 (Oct-4, Klf-4 and Sox-2) original Yamanaka factors (Takahashi and Yamanaka, 2006), 
followed by assessment of AP and Nanog staining (Figure 4.10A-C). iPS cell reprogramming 
with 4 factors resulted in no significant difference in AP and Nanog staining between wild-type 
and TKO (Figure 4. 10A-C), while iPS cell reprogramming with 3 factors generated 2 and 4 AP 
positive clones in wild-type and TKO TTFs respectively. To rule out the possibility that TTFs 
may behave differently from MEFs in reprogramming process, TTFs from heterozygous and 
homozygous p53 deficient mice were isolated and subjected to iPS cell reprogramming. 
Consistent with previous findings, loss of p53 dramatically improved reprogramming efficiency 
along with increased proliferation in TTFs (Figure 4. 10D and E). Notably, mir-34 deficiency 
caused increased proliferation rate similar to that resulting from p53 inactivation. These findings 
indicate that p53 effects on iPS cell reprogramming are not limited to accelerated proliferation   
(Figure 4.10A-C and E). 
Since TTFs have a less replicative potential than MEFs, we further explored the iPS cell 
reprogramming efficiency with MEFs. In addition, to reduce technical biases from different MEFs 
preparation and strain backgrounds, MEFs from mir-34aloxP/loxPmir-34b/cloxP/loxP were infected with
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Figure 4.10 iPS cell reprogramming efficiency of TTFs from wild-type and TKO. A and B. 
TTFs from TKO and age-matched wild-type mice were isolated, subjected to iPS cell 
reprogramming with Oct-4, Sox-2, Klf-4 and c-Myc and stained with AP and Nanog respectively. 
C. Relative iPS cell reprogramming efficiency from three independent experiments was 
quantified. D. TTFs from heterozygous and homozygous p53 deficient mice were used for iPS 
cell reprogramming. p53 deficiency increases iPS cell reprogramming efficiency (P=0.01). 
Relative iPS cell reprogramming was quantified based on AP-positive colony numbers 
compared to control experiments. E. Cell growth curves after induction of iPS cell 
reprogramming factors by doxycycline. Note similar growth rates between p53 and mir-34 
deficiency. Bars, SD. iPS cell reprogramming, AP staining and cell growth analysis were 
performed by Christian Abratte, Cornell Induced Pluripotent Stem Cell Core Facility.  
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either Ad-Blank or Ad-Cre, and subjected to iPS cell reprogramming with four factors. 
Consistent with TTFs iPS cell reprogramming results, there was no statistically significant 
difference between wild-type and mir-34 null MEFs (Fig. 4.11). 
 
4.4.5 miR-34a expression and DNA damage response 
  
In order to explore potential involvement of miR-34a in response to IR, wild-type mice were 
exposed to 15 Gy and subjected to histological analysis (Figure 4. 12) and miR-34a in situ 
hybridization (Figure 4.13). 1, 3, and 5 days after irradiation. Consistent with previous studies 
(Komarova et al., 2004; Martin et al., 1998), in the small intestine, the size and number of 
intestinal crypts was markedly decreased 3 days after IR (Figure 4. 12C and G) and significant 
destruction of villi was observed in 5 days after IR (Figure 4.12D and H). At the same time, 
intestinal crypts of the large intestine were less damaged as compared to the small intestine 
(Figure 4. 12J-L). On day 5, hyperplastic regenerative crypts were observed both in small and 
large intestine (Figure 4. 12D, H and L). Differential responses from small and large intestine 
after 15 Gy of IR are consistent with previous reports that large intestine is less sensitive than 
small intestine in DNA damage response (Hong et al., 2005; Merritt et al., 1997; Potten et al., 
1997). 
 Next, we investigated miR-34a expression in the small and large intestine after 15 Gy of 
IR (Figure 4. 13). While miR-34a was not detectable in the large intestine without IR, miR-34a 
was expressed in both villi and crypts in the proximal and distal part of small intestine (Figure 4. 
13A, E and I). miR-34a expression was found mainly in the crypts of all intestinal regions one 
day after IR (Figure 4. 13B, F and J). Along with decreased number of small intestinal crypts, 
the levels of miR-34a were markedly reduced 3 days after IR, particularly in the small intestine  
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(Figure 4. 13C and G). However, as regenerative crypts appeared 5 days after IR, miR-34a 
levels became high in hyperplastic enterocytes (Figure 4. 13D, H and L). Notably, miR-34a 
expressing cells tended to move towards villi (Figure 4. 13D and H). Overall pattern of miR-34a 
expression, with preferential presence of miR-34a in the crypt region after IR was similar in 
small and large intestine, but the number of intestinal crypts in the large intestine was not 
decreased 3 days after IR. 
Given the expression pattern of miR-34a in GI tract after IR, we hypothesized that miR-
34 may play a role in DNA damage response to IR. To initiate exploration of this role, 4 weeks 
old miR-34b/c-/- female mice and their wild-type littermates were subjected to 10 Gy 
(hematopoietic syndrome) and 15 Gy (gastrointestinal tract syndrome) of IR. While 10 Gy dose 
exposure did not show any difference in survival between wild-type and mir-34b/c-/- mice (Figure 
4.14A), mir-34b/c-/- mice showed IR-resistant phenotype after 15 Gy IR exposure (Figure 4.14B).  
 
4.5 Discussion 
 
In order to study the role of miR-34 in development and carcinogenesis, we have prepared mice 
with both conventional and conditional inactivation of mir-34. While mice completely lacking 
miR-34 family are alive, conventional knockout approach has several potential shortcomings.  
Among those are potential abnormalities during postnatal development and ageing which may 
make it impossible to study gene function in the cell type of choice. Furthermore, non-
physiological adaptive responses from a specific gene knock-out may obscure the study of gene 
function (Williams and Wagner, 2000). 
One of major limitations for generation of conditional knockout mice is the difficulty and 
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 Focal hyperplasia of Purkinje cells in cerebellum also raise a possibility that miR-34 
plays a role in cerebellar development. Given tissue specific expression pattern of miR-34 in 
Purkinje neurons (Corney, 2010), hyperplasia of Purkinje cells may result from miR-34 
deficiency. Interestingly, such Purkinje neuron hyperplasia has been reported in Bcl-2 
transgenic mice (Zanjani et al., 1996). Bcl-2 has anti-apoptotic functions, playing a critical role in 
determining cell survival and death (Kelly and Strasser, 2011), and also one of the miR-34 
targets (Ji et al., 2009). It is known that mouse Purkinje cells express Bcl-2 from E 18.5 until the 
first postnatal month, and then expression of Bcl-2 declines substantially by 5 months (Merry et 
al., 1994). Thus, it is tempting to speculate that mir-34 deficiency results in increased Bcl-2 
expression, and subsequently causes hyperplasia of Purkinje cells similar to phenotype of Bcl-2 
transgenic mice. Since Bcl-2 transgenic mice exhibited decreased RotaRod performance 
despite increased number of Purkinje cells (Goswami et al., 2005), it would be interesting 
whether mir-34 deficiency causes any defects related to motor neuron disease. 
 Ulceration of forestomach and hyperplasia of the surrounding gastric squamous 
epithelium in TKO mice raises a possibility that mir-34 deficiency may cause imbalance between 
gastric epithelial cell proliferation and death in maintaining gastric mucosal integrity. Since miR-
34 also involves in anti-proliferative function, it is possible that loss of mir-34 alters the balance 
between proliferation and apoptosis toward proliferative, resulting in hyperplasia and gastric 
ulcer. Alternatively mir-34 deficiency may cause inflammation and/or a defect in epithelial 
regeneration, followed by hyperplasia. Interestingly, p63 deficiency has been shown to result in 
metaplasia of the squamocolumnar junction (Wang et al., 2011). At the same time, p63 also has 
been known to regulate miR-34a expression (Su et al., 2010). Since esophageal and gastric 
adenocarcinomas are associated with chronic inflammation and are preceded by robust 
metaplasia, it is of interest whether this is connected to esophageal or gastric cancer 
development. 
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By 6 month of age no overt malignant lesions have been detected by us in mice lacking 
all miR-34 members. Since the majority of epithelial cancers develop by 1-1.5 years of age long-
term experiments should clarify if miR-34 plays an important role in cancer initiation. However, 
lack of hematopoietic malignancies, such as leukemias and lymphomas, typical for p53 null 
mice indicates that tumor suppressive functions of miR-34 and p53 are quite different. 
Based on our observations that miR-34a expression was downregulated regardless of 
p53 mutational status in ovarian cancers (described in Chapter 2), it is also possible that loss of 
miR-34 may cooperate with p53 mutation in carcinogenesis, albeit miR-34 is a downstream in 
p53 signaling. Furthermore, as we describe in Chapter 3, deficiency for p53 and miR-34 
cooperate in elevation of MET expression resulting in increased cell invasion. Whether miR-34 
loss combined with p53 loss increases immortalization process in cell culture system and tumor 
susceptibility in vivo would be among our next questions to be addressed. 
Since iPS cells were generated from somatic cells by Yamanaka group (Takahashi and 
Yamanaka, 2006), a number of studies aimed to improve reprogramming efficiency, to reduce 
required factors, to utilize easily accessible cells as a source and to ensure safety issues, such 
as malignant transformation, have been reported (Gonzalez et al., 2011). A number of groups 
showed that loss of p53 accelerates reprogramming process (Hanna et al., 2009; Hong et al., 
2009; Kawamura et al., 2009; Li et al., 2009a; Marion et al., 2009; Utikal et al., 2009). Hanna et 
al. proposed two different pathways to improve iPS cell reprogramming efficiency via 
proliferation-dependent and –independent way. While Nanog expression facilitates iPS cell 
reprogramming process itself in proliferation-independent manner, the effect of p53 loss was 
largely proliferation-dependent (Hanna et al., 2009). However, it is still possible that p53 may 
affect iPS cell reprogramming process itself, since p53 is also known to regulate stem cell 
differentiation and stemness gene expression such as Oct-4 and Nanog (Lin et al., 2005; Qin et 
al., 2007). According to literature reports (Christoffersen et al., 2010; Kong et al., 2008; 
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Lujambio et al., 2008) and our unpublished data (Hwang et al.), miR-34 family is able to target 
c-Myc and Klf-4, two of the four initially identified reprogramming factors. We reasoned that mir-
34 inactivation may lead to increased expression of c-Myc and Klf-4 thereby resulting in 
improved iPS cell reprogramming efficiency. However we did not observe the anticipated effect.  
Unlike p53 deficiency, mir-34 deficiency did not improve reprogramming of TTFs. Notably, TTFs 
deficient for with p53 or all miR-34 has similarly increased proliferation rate suggest that 
increased proliferation is not the only mechanism by which p53 deficiency improves 
reprogramming efficiency. Our observations that mir-34 null MEFs or OSE were not easily 
immortalized in cell culture (Hwang et al., unpublished) indicate that unlike p53 deficiency, mir-
34 inactivation may not be sufficient to overcome the senescence barrier. It remains to be 
determined if elimination of senescence barrier is the only additional mechanism by p53 
counteracts reprograming. It is also remains to be established if introduction of miR-34 to cells 
undergoing reprogramming may attenuate this process. 
p53 activation by DNA damage such as IR leads to apoptosis, cell cycle arrest and 
senescence, although responses are highly cell-type dependent and dose-dependent (Gudkov 
and Komarova, 2010). In the mouse, 10 Gy of IR causes hematopoietic syndrome. The 
deleterious effects of this syndrome are largely mediated by p53 because p53 deficiency results 
in extended mouse survival. On the contrary,  high dose of IR (>15 Gy), which results  in 
gastrointestinal (GI) tract syndrome associated with shorter survival of p53 deficient mice, 
indicating the radioprotective role of p53 (Komarova et al., 2004). Komarova et al. proposed that 
the balance of two functions, growth arrest and apoptosis induced by p53 may determine 
radiation-induced injury and its final outcome (Komarova et al., 2004), albeit it remains unclear 
how p53 differentially responds in different tissues and doses, and which downstream targets of 
p53 are responsible for these outcomes. As a p53 downstream target gene, p21 deficiency has 
been shown to have a similar radiosensitive phenotype of p53 deficiency in 15 Gy IR (Komarova 
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et al., 2004). At the same time, loss of PUMA, another target of p53 has been shown to induce 
radioresistant phenotype in GI tract syndrome (Qiu et al., 2008). Therefore, the effect of 
downstream targets of p53 may be different depending on its specific role in tissues. 
  Our findings of differential expression pattern of miR-34a in the small and large intestine 
after 15 Gy whole body exposures of IR, are in agreement with previous observations that the 
small intestine is more sensitive than large intestine after 15 Gy IR (Potten et al., 1997). In the 
small intestine we observed that miR-34a expressing cells were almost depleted 3 days after IR, 
likely due to IR-induced apoptosis and cell death. Notably, regenerating crypts highly expressed 
miR-34a 5 days after IR. In the case of large intestine, miR-34a expressed in the crypt region 1 
day after IR, and miR-34a expressing cells seemed to move toward villi without depletion of 
miR-34a expressing cells. Interestingly, as opposed to miR-34a expression pattern, Bcl-2 is 
expressed in the large intestine crypt location of stem cells but not in that of small intestine 
(Merritt et al., 1997). In addition, differential expression pattern of Bcl-2 in the small and large 
intestine has been proposed as the reason for differential ability of these regions to induce 
apoptosis after IR (Potten et al., 1997). Thus, it is also possible that differential miR-34a 
expression pattern may account for differential sensitivity to induce apoptosis after IR.  
Accordingly, our finding that mir-34b/c knock-out mice exhibited radioresistance in 15 Gy but not 
10 Gy, as compared to littermate wild-type mice, may be due to increased Bcl-2 expression 
resulting from mir-34b/c inactivation. Unfortunately, our in situ hybridization failed  to detect miR-
34b/c in GI tract so far, consistent with overall low levels of expression of these miRNAs in the 
intestinal epithelium with miR-34b/c GI tract expression being reported only in 14.5 embryo 
(Diez-Roux et al., 2011).  We are currently evaluating DNA damage response in mir-34a-/- and 
mir-34a-/- mir-34b/c-/- mice. These studies, together with identification of involved downstream 
targets, should determine the role of miR-34 pathogenesis of DNA damage response in the GI 
tract syndrome.  
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Taken together, we report the initial characterization of mir-34 deficient mice including 
defects in hematopoietic system development, focal hyperplasia of Pukinje neurons and gastric 
ulceration. Failure of mir-34 loss to recapitulate the p53 loss phenotype in iPS cell 
reprogramming may provide a clue for the proliferation-independent mechanism of p53 in iPS 
cell reprogramming process. Further studies on DNA damage response and detailed 
characterization of newly developed mir-34 conditional and conventional knock-out mice will 
reveal the role of miR-34 in development, DNA damage response and carcinogenesis. 
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CHAPTER 5 
 
SUMMARY AND FUTURE DIRECTIONS 
 
5.1 Summary 
 
Previous observations by us and others have shown that p53 transcriptionally activates genes 
encoding for miR-34 family. Furthermore, it has been reported that miR-34 expression is 
frequently downregulated in several types of cancer. Thus, we hypothesized that miR-34 family 
expression would be affected in high grade serous ovarian adenocarcinomas, particularly since 
p53 mutation is the most common genetic alteration in this type of cancer. Indeed we found that 
miR-34 family expression is frequently downregulated in EOC. Additionally, we have further 
identified epigenetic inactivation or copy number variations of miR-34 family and found that miR-
34b/c is associated with disease progression. Interestingly, while downregulation of miR-34b 
and c correlated with presence of p53 mutation, miR-34a is frequently downregulated even in 
cancers with wild-type p53. These observations indicate that miR-34 may have p53 independent 
role in cancer pathogenesis. We have also observed inverse correlation between expression of 
miR-34a and its predicted target MET expression in human EOC specimens, suggesting that 
reduced miR-34a expression is responsible for increased MET expression. To confirm this 
possibility we have reconstituted p53 deficient cells, whose miR-34 family expression was 
significantly reduced, with miR-34 precursor molecule and shown that such reconstitution 
reduces MET expression. Indicating importance of miR-34 of cancer suppression, reduction of 
MET expression significantly diminishes cell migration and invasion. 
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These studies, together with literature reports of frequent p53 mutations, high level of 
MET expression and their association of these alterations with poor prognosis in EOC, have 
indicated that p53/miR-34/MET pathway plays a crucial role in epithelial ovarian carcinogenesis. 
To further explore p53/miR-34/MET regulation in EOC, we have inactivated p53 in OSE cells 
and studied MET expression, cell motility and invasion by using primary OSE cells from 
p53loxP/loxP mice. Consistent with previous observations, MET expression is increased soon after 
p53 inactivation in vivo, as well as in OSE cell culture. Importantly, increased motility and 
invasion resulting from p53 inactivation is abrogated by Met inactivation, indicating that p53 
controls cell motility and invasion dependents on regulation of MET expression. By using 
primary OSE cells deficient for all miR-34 family (see below) we have directly shown that in 
addition to earlier observations of miR-34-mediatred MET regulation by p53, it also regulates 
MET by miR-34 independent mechanisms. We have determined that in the latter variant p53 is 
able to repress MET promoter activity through transcriptional factor Sp1, and shown that p53 
may inhibit Sp1 DNA binding through protein-protein interactions. Notably we have shown that 
several p53 proteins containing various DNA binding domain mutations retain MET promoter 
suppression, thereby resulting in somewhat lower expression levels of MET as compared to 
cells null for p53. This finding may provide mechanistic explanation to reports of poorer 
prognosis of patients with p53 null EOC, as compared to those expressing mutant p53 (Rose et 
al., 2003; Shahin et al., 2000; Sood et al., 1999). 
In order to study the precise role of miR-34 as a potential tumor suppressor in vivo, we 
have generated mir-34a conditional knock-out mice, and obtained conventional and conditional 
mir-34 family knock-out mice in a collaboration with David Corney (our laboratory) and Dr. Heiko 
Hermeking (Ludwig-Maximilians-University Munich). We have demonstrated that mice lacking 
all mir-34 genes are alive, similar to p53 null mice. However, our initial pathological evaluation 
indicates that mir-34 null mice have pathological alterations distinct from those associated with 
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p53 deficiency. Unlike early onset lymphomas typical for p53 null mice, mir-34a-/-mir-34b/c-/- 
mice have hypoplasia of the spleen, accelerated aplasia in the thymus, focal hyperplasia of the 
Purkinje cells and ulcerations in the forestomach. We have also determined that unlike p53 mir-
34 null cells do not accelerate iPS cell reprogramming and may have different response to DNA 
damage by IR. These results provide essential basis for further elucidation of miR-34 biological 
functions in normal development and carcinogenesis. 
 
5.2 Future directions 
5.2.1 miR-34 and therapeutics in clinically relevant settings 
 
p53 gene delivery by adenovirus has failed due to multiple genetic and epigenetic 
dysregulations in cancer patients, negative cross-talk between delivered wild-type p53 and 
dominant negative form of mutant p53, and interaction with p63/p73 (Zeimet and Marth, 2003). 
Our studies indicate that other means such as miR-34 delivery could be appealing alternatives 
to p53 based gene therapy. 
 In Chapter 2, we showed frequent downregulation of miR-34 family in ovarian cancer 
patients. In addition, reconstitution of miR-34 expression could reduce cancer cell proliferation, 
migration and invasion, suggesting a possibility of miR-34 delivery as a therapeutic agent in 
cancers, such as EOC with reduced miR-34 expression. Although downregulation of miR-34b/c 
was highly associated with p53 mutational status, we found that cancers harboring wild-type 
p53 frequently also had reduced miR-34a expression as compared to normal human OSE cells. 
Moreover, regardless of p53 status, some patients had methylation of mir-34 promoters and 
gene copy number variations, suggesting that miR-34 biological functions regulated 
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independently of p53 are also important for cancer pathogenesis. Consistent with this possibility, 
miR-34 regulation by other transcription factors, such as c-Myc, ELK1 and C/EBPα, has been 
reported (Chang et al., 2008; Christoffersen et al., 2010; Pulikkan et al., 2010). Interestingly, in 
the case of pleural mesothelioma, characterized by rare p53 mutation, CpG island methylation 
of miR-34 promoter region is frequent and associated with reduced expression (Kubo et al., 
2011). Taken together, recent data from various types of cancers suggest that miR-34 can be 
regulated by p53-independent mechanism and downregulation of miR-34 in malignancies 
frequently occurs regardless of p53 mutational status. Despite sequence similarity and several 
shared targets of miR-34 family, individual miR-34 family may have different targets and effects 
when expressed (Cole et al., 2008). Therefore, it is reasonable to further test the effect of 
individual miR-34 delivery for cancer therapy in mouse models. 
 In order to explore therapeutic potential of miR-34 in animal models, it is required to 
have accurate animal models and experimental system to address this issue. Previously our 
laboratory have reported a model of EOC peritoneal dissemination initiated by intraperitoneal 
injection of neoplastic OSE cells (Williams et al., 2010). This system has several advantages 
over other experimental disease progression models. First, primary OSE cells derived from 
genetically modified mice are far better genetically defined, unlike human cancer cell lines, 
which usually have numerous passenger mutations. Second, unlike human cancer cell lines 
xenografted into immunocompromised mice, neoplastic OSE cells can be injected into 
immunocompetent syngeneic mice, allowing tumor development in physiologically adequate 
microenvironments. Using newly developed mir-34 knock-out mice in conjunction with other 
genetic alterations, we are able to generate neoplastic OSE cells with either intact miR-34 
expression or miR-34 deficiency. Furthermore, lentivirally infected GFP expression system 
enables us to monitor tumor growth and regression in live animals. Since introduction of 
lentiviral vectors usually results in the heterogeneity in transgene expression levels among cells 
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due to differences in the position of their integration, we will use a modified pINDUCER lentiviral 
vector  (Figure 5.1) (Meerbrey et al., 2011). This vector will allow controlled miRNA-expression 
by tetracycline/doxycycline controlled reverse transactivator (rtTA) in parallel with expression of 
two reporter genes. Thus both integrated vector and miRNA induction can be tracked by 
different fluorescences. Along with lentiviral system, in collaboration with Dr. Moonsoo Jin lab, 
we are developing nanoparticle-mediated miR-34 delivery in ovarian cancer models. In this way, 
we can systemically deliver miRNAs and evaluate the effect of miR-34 delivery and side effects. 
Therefore, taking advantages of newly developed mir-34 conditional knock-out mice, new 
generation of inducible lentivirus system and nanotechnology to deliver miRNAs, we will be able 
to examine the therapeutic potential of miR-34 in EOC. 
 
5.2.2 p53/miR-34/Met pathway in early carcinogenesis 
 
It is obvious that MET regulation is important in carcinogenesis, since its overexpression is 
frequently associated with poor prognosis in several different types of cancers including ovarian 
carcinoma (Masuya et al., 2004; Sawada et al., 2007; Tolgay Ocal et al., 2003). Various 
approaches to regulate MET by antibody, siRNA or small molecules have been in  clinical trials 
(Comoglio et al., 2008). Importance of MET regulation could be further supported by our finding 
that p53 has dual regulation of MET via miR-34-dependent and -independent pathways. It has 
been proposed that this type of redundancy, also known as feedforwardloop regulation,   
ensures prevention of leaky expression (Hornstein and Shomron, 2006; Stark et al., 2005; 
Tsang et al., 2007). Therefore, by using feedforward loop regulation of MET, p53 is able to 
tightly regulate MET expression both on transcriptional and post-transcriptional levels. 
Identification of MET as an important target of p53 in EOC has two significant implications.  
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 First, our studies show that metastatic traits such as cell motility and invasion mediated 
by MET could be acquired during early stages of carcinogenesis initiated by p53 mutations. 
These findings support a recent shift in paradigm of sequential cancer progression. According to 
the classical carcinogenesis model, metastatic traits have been thought to be acquired at  late 
stages of carcinogenesis (Gupta and Massague, 2006). However growing number of evidences 
point to a possibility that some neoplastic cells may have metastatic ability already during the 
early stages of carcinogenesis  (Eyles et al., 2010; Podsypanina et al., 2008; Schardt et al., 
2005; Weinberg, 2008). This might explain the reason for fast progression and difficulties to 
identify precursor lesion of high grade serous type EOC.  
 Second, it has been far less appreciated that wild-type p53 is a critical regulator of cell 
motility and invasion, albeit Rho family of small GTPase has been implicated in cell motility as a 
p53 function (Gadea et al., 2007; Gadea et al., 2002; Gadea et al., 2004). Rather, gain-of-
function mutation of p53 has been considered to be associated with metastatic traits (Brosh and 
Rotter, 2009; Olive et al., 2004; Oren and Rotter, 2010). Our finding that wild-type p53 controls 
cell motility and invasion mainly through MET sheds light on these less appreciated functions 
and may facilitate use of p53 molecular signatures for disease prognosis. Prediction of patient 
prognosis based on p53 mutational status has been controversial (Soussi and Beroud, 2001). 
However a number of evidences consistently indicate that p53 null mutations are associated 
with the worst course of cancer progression as compared to mutations resulting in expression of 
mutant p53 in lung, breast and ovarian carcinoma (Hashimoto et al., 1999; Lai et al., 2004; 
Olivier et al., 2006; Pavel et al., 2008; Rose et al., 2003; Shahin et al., 2000; Sood et al., 1999). 
In Chapter 3, our studies have shown molecular mechanism which may explain differential 
prognosis based on p53 mutational status (Figure 5.2). 
 Since DNA binding domain mutant p53 still retains partial suppression of MET promoter 
but loses transactivation of miR-34, MET expression would be less affected, likely leading to 
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more limited invasive and metastatic properties of neoplastic cells, as compared to those in p53 
null cancers (Figure 5.2). Therefore, it would be of interest to determine if affecting individual 
components of feedforward loop regulation of MET will result in differential MET expression and 
prognosis in human ovarian cancer carrying different types of p53 mutations. In addition, it 
would be interesting to study if this feedforward loop regulation is also found in other types of 
normal and neoplastic cells. Our preliminary studies on colon and lung cancer cell lines suggest 
that such regulation of MET does exist in other types of cancer (Chapter 3). 
With regard to miR-34-independent mechanism, the involvement of Sp1 may lead to a 
novel approach for regulation of MET expression. Both mithramycin A treatment to inhibit Sp1 
DNA binding and Sp1 knockdown by siRNA generate similar effects on MET expression and 
promoter activity (Papineni et al., 2009; Verras et al., 2007; Zhang et al., 2003). Recently, 
tolfenamic acid, a small molecule of Sp1 inhibitor, which is able to induce Sp1 family protein 
degradation has been identified (Colon et al., 2011). Expectedly, this inhibitor downregulates 
MET expression in cancer cells, including ovarian cancer cells (Basha et al., 2011; Papineni et 
al., 2009). Interestingly, we have observed that some cancers harboring p53 also highly express 
MET. In the case of ovarian cancer cell line OVCA433 the enrichment of Sp1 on the proximal 
region of MET promoter likely results in MET overexpression (our unpublished data). This data 
suggests that there is an alternative pathway to increase MET expression by recruitment of Sp1 
in the promoter region. Consistent with this possibility, we observed continuous increase in MET 
expression after p53 inactivation with the highest expression of MET in late passage cells 
(Chapter 3). Detailed understanding of p53/miR-34/MET pathway and the involvement of Sp1 in 
miR-34-independent regulation of MET should pave the road toward alternative therapeutic 
approaches. 
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5.2.3 The role of miR-34 in development, carcinogenesis and DNA damage response 
 
It is not completely surprising that mir-34a-/-mir-34b/c-/- mice are grossly normal and did not 
show any embryonic lethality, since p53-/- mice are also grossly normal and lack any observable 
gross defects (Donehower et al., 1992). At the same time, our initial observations indicate that  
miR-34 family may have a different role in development and/or carcinogenesis. In our 
preliminary data, one of the obvious observations was an abnormality in hematopoietic system, 
thymus and spleen. Thymus from 9 weeks old mir-34 deficient mice undergoes accelerated 
aplasia, and spleen showed hypoplasia and/or aplasia of white pulp. In accordance with our 
observations, miR-34a has been shown to be involved in B and T cell development (Rao et al., 
2010; Stadanlick et al., 2011). In particular, ectopic expression of miR-34a blocked pro-B-cell-to-
pre-B-cell transition in B cells and induced arrest of T cells. It is reasonable to hypothesize that 
elevation of a certain miR-34 target proteins may result in this phenotype. Rao et al. further 
demonstrated that blocked B cell development by miR-34a might be due to decreased level of 
FoxP1, a novel target of miR-34a (Rao et al., 2010). Therefore, further examination on FoxP1 
expression and B cells development may explain an observed splenic phenotype of in mir-34a-/- 
mir-34b/c-/-mice. Accelerated thymic aplasia has been observed in TNF and IL-10 transgenic 
mice (Liepinsh et al., 2009; Rouleau et al., 1999). It is tempting to speculate that miR-34 family 
has certain unidentified target genes among cytokine-related genes, whose gene expression 
were increased in the thymus of mir-34a-/- mir-34b/c-/- mice. Therefore, identification of cytokine-
related genes targeted by miR-34 could be one of areas of future interest.  
Based on tissue distribution of miR-34a and miR-34b/c, miR-34b/c is highly enriched in 
testis and has been implicated in spermatogenesis (Bouhallier et al., 2010), while miR-34a is 
ubiquitously expressed throughout tissues (Diez-Roux et al., 2011). However, mir-34b/c-/- mice 
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showed no gross abnormalities in testis and fertility, suggesting that miR-34a might compensate 
for loss of miR-34b/c in testis. Consistent with this possibility, our preliminary results showed 
lower fertility in mir-34a-/-mir-34b/c-/- mice, albeit it is too early to make any conclusion. This 
observation raises a question what is the precise role of miR-34 in spermatogenesis.  
It is also tempting to speculate its potential role in stem and/or progenitor cells. 
According to literature reports (Christoffersen et al., 2010; Kong et al., 2008; Lujambio et al., 
2008) and our unpublished data from our laboratory (Chang-il Hwang, David Corney, Kirsten 
Elzer, and Alexander Nikitin) miR-34 has been predicted and experimentally validated to target 
Klf-4 and c-Myc, which are required transcription factors for iPS cell reprogramming. In addition, 
other studies indicate adult stem cells of some tissues may have higher expression of miR-34 
family (David Corney, Samantha Palmaccio, Chang-Il Hwang, and Alexander Nikitin, 
unpublished). In agreement with these observations, Notch1, Notch2 and Jag1 have been 
shown as targets of miR-34 (Lewis et al., 2003; Pang et al., 2010). Exhausting of 
stem/progenitor cell pool could be a one of the reason for thymic and spleen hypoplasia 
observed in mice null for all mir-34 genes. Therefore, the effect of mir-34 inactivation in diverse 
tissue stem cells is worth to be explored. 
To evaluate role of mir-34 in carcinogenesis we plan to cross mir-34aloxP/loxPmir-
34b/cloxP/loxP mice with tissue-specific Cre transgenic mice, such as PB4-Cre to induce gene 
inactivation in prostate epithelium (Wu et al., 2001), and MMTV-Cre to induce gene inactivation 
in mammary epithelium (Cheng et al., 2010). To study ovarian carcinogenesis, intrabursal 
administration of Ad-Cre allows inactivation of mir-34 in OSE (Flesken-Nikitin et al., 2003). 
Since mir-34a-/-mir-34b/c-/- mice did not develop spontaneous tumors by 6 months after birth 
unlike p53 deficient mice (Donehower et al., 1992), we will also introduce other genetic 
alterations such as p53 and/or Rb mutations, and expression of mutated K-Ras to see if miR-34 
cooperates with other tumor suppressors or oncogenes. 
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Given survival difference of mir-34b/c-/- in 15 Gy of whole body irradiation, it seems to be 
obvious that miR-34 family plays an important role in gastrointestinal tract syndrome induced by 
ionizing radiation (IR). Comprehensive analysis of the effect of IR on intestinal epithelium 
including apoptosis, proliferation and senescence should be carried out. Although we were not 
able to see survival difference in 10 Gy of IR for hematopoietic syndrome, it is worth to explore 
the effect of 10 Gy whole body irradiation on mir-34a-/- and mir-34a-/- mir-34b/c-/- mice. Since 
miR-34a has been connected to B and T cell development as described above and our results 
suggest that miR-34 appears to play a role in hematopoietic system development, we may be 
able to see some differences in hematopoietic syndrome induced by 10 Gy of IR. In addition, 
since thymic accelerated aplasia has been observed in 9 weeks oldmir-34a-/-mir-34b/c-/- mice 
but not at 3 weeks of age, DNA damage response in different age of mir-34a-/-mir-34b/c-/- mice 
will be subjected to our next studies. 
In conclusion, we have explored the role of p53/miR-34/MET pathway in ovarian cancer 
specimens, demonstrating that frequent downregulation of miR-34 is mainly associated with p53 
mutation and MET overexpression. Our project to utilize primary OSE cells from genetically 
modified mice as an early model of ovarian carcinogenesis allowed us to identify p53 as a 
master regulator of cell motility and invasion, and to show that MET signaling is essential 
component of such regulation. Also we have shown that p53 is able to regulate MET via miR-
34-dependent and miR-34-independent mechanisms. In order to directly prove a hypothesis that 
miR-34 is a tumor suppressor, we have generated mir-34a conditional knock-out mice and are 
in the process of characterization of mir-34a-/- mir-34b/c-/- mice. Characterization of the effect of 
mir-34 inactivation in diverse tissues will allow us to evaluate the precise role of miR-34 in 
development, DNA damage response and carcinogenesis. 
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